

**Clinical trial results:****FLUTicasone in Eosinophilic esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects with Eosinophilic Esophagitis****Summary**

EudraCT number	2016-004749-10
Trial protocol	BE DE ES
Global end of trial date	23 October 2019

**Results information**

Result version number	v1 (current)
This version publication date	03 April 2022
First version publication date	03 April 2022

**Trial information****Trial identification**

Sponsor protocol code	SP-1011-002
-----------------------	-------------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03191864
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Adare Pharmaceuticals US, LP
Sponsor organisation address	1200 Lenox Drive, Suite 100, Lawrenceville, United States, 08648
Public contact	Project Management, IQVIA, Inc. (formerly QuintilesIMS), +34 934894035, ensayosclnicos@quintiles.com
Scientific contact	Project Management, IQVIA, Inc. (formerly QuintilesIMS), +34 934894035, ensayosclnicos@quintiles.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 October 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	03 January 2019
Global end of trial reached?	Yes
Global end of trial date	23 October 2019
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the study is to evaluate the efficacy (histological response) of APT-1011 in adults with eosinophilic esophagitis (EoE).

Protection of trial subjects:

FLUTE was conducted according to the principles of the Declaration of Helsinki (Seoul, October 2008), and the ICH guidelines for GCP. The Sponsor ensured that the study complies with all local, federal, or country regulatory requirements as applicable.

Background therapy:

Not applicable.

Evidence for comparator:

Not applicable.

Actual start date of recruitment	22 June 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	Spain: 35
Country: Number of subjects enrolled	Germany: 9
Country: Number of subjects enrolled	Canada: 12
Country: Number of subjects enrolled	United States: 249
Country: Number of subjects enrolled	Switzerland: 2
Worldwide total number of subjects	308
EEA total number of subjects	45

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	296
From 65 to 84 years	12
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Recruitment in 6 countries (United States, Canada, Belgium, Germany, Spain, and Switzerland) took place between 22-Jun-2017 (First Subject Enrolled) until 23-Aug-2018 (Last Subject Enrolled).

### Pre-assignment

Screening details:

The Screening Period was 4 weeks (28 days). Along with the reports confirming the subject's primary diagnosis of EoE, the Investigator assessed eligibility criteria of the subject based on screening results. The Global EoE Symptom Score had to be  $>3$  for the subject to continue in the study.

### Period 1

Period 1 title	Baseline Symptom Assessment
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Placebo Run-in
-----------	----------------

Arm description:

Due to the high placebo response rates, the study utilized a 4-week single-blind placebo run-in period to not only establish the baseline symptoms for the study, but also to ensure that all subjects enrolled had sufficient severity of EoE to warrant inclusion in the study.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

All subjects received placebo 30 minutes after breakfast and HS (at bedtime) daily.

Number of subjects in period 1	Placebo Run-in
Started	308
Completed	106
Not completed	202
Consent withdrawn by subject	19
Violation of inclusion/exclusion criteria	179
Adverse event, non-fatal	2
Other	2

**Period 2**

Period 2 title	Part 1 - Induction
Is this the baseline period?	Yes <sup>[1]</sup>
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

**Arms**

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	APT-1011 1.5 mg HS
------------------	--------------------

## Arm description:

Subjects received placebo 30 minutes after breakfast and 1.5 mg APT-1011 HS (at bedtime) daily

Arm type	Experimental
Investigational medicinal product name	APT-1011
Investigational medicinal product code	
Other name	fluticasone propionate
Pharmaceutical forms	Tablet
Routes of administration	Oral use

## Dosage and administration details:

Subjects received 1.5 mg APT-1011 HS (at bedtime) daily

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

## Dosage and administration details:

Subjects received placebo 30 minutes after breakfast daily

<b>Arm title</b>	APT-1011 1.5 mg BID
------------------	---------------------

## Arm description:

Subjects received 1.5 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 3.0 mg

Arm type	Experimental
Investigational medicinal product name	APT-1011
Investigational medicinal product code	
Other name	fluticasone propionate
Pharmaceutical forms	Tablet
Routes of administration	Oral use

## Dosage and administration details:

Subjects received 1.5 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 3.0 mg

<b>Arm title</b>	APT-1011 3 mg HS
------------------	------------------

## Arm description:

Subjects received placebo 30 minutes after breakfast and 3.0 mg APT-1011 at bedtime daily

Arm type	Experimental
Investigational medicinal product name	APT-1011
Investigational medicinal product code	
Other name	fluticasone propionate
Pharmaceutical forms	Tablet
Routes of administration	Oral use

## Dosage and administration details:

Subjects received 3.0 mg APT-1011 at bedtime daily

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received placebo 30 minutes after breakfast daily	
<b>Arm title</b>	APT-1011 3 mg BID

Arm description:

Subjects received 3 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 6.0 mg

Arm type	Experimental
Investigational medicinal product name	APT-1011
Investigational medicinal product code	
Other name	fluticasone propionate
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 3 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 6.0 mg

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Subjects received placebo 30 minutes after breakfast and HS (at bedtime) daily

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received placebo 30 minutes after breakfast and HS (at bedtime) daily

Notes:

[1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: Period 1 is the Placebo Run-in period where a 4-week baseline symptom assessment has been completed. 308 subjects entered this period but only 106 completed, the majority due to the fact that there was a violation of inclusion/exclusion criteria in the study. For that reason, we believe it is most appropriate to count Period 2 as the baseline period and to report the baseline characteristics for those participants who were randomized into the study and comprise the FAS, as presented in the CSR.

<b>Number of subjects in period 2<sup>[2]</sup>[3]</b>	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS
Started	21	22	21
Completed	17	20	19
Not completed	4	2	2
Consent withdrawn by subject	3	1	1
Adverse event, non-fatal	-	1	-
Other	1	-	1

<b>Number of subjects in period 2<sup>[2]</sup>[3]</b>	APT-1011 3 mg BID	Placebo
Started	20	19

Completed	19	17
Not completed	1	2
Consent withdrawn by subject	-	1
Adverse event, non-fatal	1	1
Other	-	-

Notes:

[2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Period 1 is the Placebo Run-in period where a 4-week baseline symptom assessment has been completed. 308 subjects entered this period but only 106 completed, the majority due to the fact that there was a violation of inclusion/exclusion criteria in the study. For that reason, we believe it is most appropriate to count Period 2 as the baseline period and to report the baseline characteristics for those participants who were randomized into the study and comprise the FAS, as presented in the CSR.

[3] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Period 1 is the Placebo Run-in period where a 4-week baseline symptom assessment has been completed. 308 subjects entered this period but only 106 completed, the majority due to the fact that there was a violation of inclusion/exclusion criteria in the study. For that reason, we believe it is most appropriate to count Period 2 as the baseline period and to report the baseline characteristics for those participants who were randomized into the study and comprise the FAS, as presented in the CSR.

### Period 3

Period 3 title	Part 2 - Maintenance
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

Blinding implementation details:

Note that those subjects that were non-responders at Week 12 were switched from another arm to the Single-blind APT-1011 3 mg BID arm. This arm was a single-blinded arm for the subjects only.

### Arms

Are arms mutually exclusive?	No
<b>Arm title</b>	APT-1011 1.5 mg HS

Arm description:

Subjects received placebo 30 minutes after breakfast and 1.5 mg APT-1011 HS (at bedtime) daily

Arm type	Experimental
Investigational medicinal product name	APT-1011
Investigational medicinal product code	
Other name	fluticasone propionate
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 1.5 mg APT-1011 HS (at bedtime) daily

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received placebo 30 minutes after breakfast daily

<b>Arm title</b>	APT-1011 1.5 mg BID
------------------	---------------------

Arm description:

Subjects received 1.5 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 3.0 mg

Arm type	Experimental
Investigational medicinal product name	APT-1011
Investigational medicinal product code	
Other name	fluticasone propionate
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 1.5 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 3.0 mg

<b>Arm title</b>	APT-1011 3 mg HS
------------------	------------------

Arm description:

Subjects received placebo 30 minutes after breakfast and 3.0 mg APT-1011 at bedtime daily

Arm type	Experimental
Investigational medicinal product name	APT-1011
Investigational medicinal product code	
Other name	fluticasone propionate
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 3.0 mg APT-1011 at bedtime daily

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received placebo 30 minutes after breakfast daily

<b>Arm title</b>	APT-1011 3 mg BID
------------------	-------------------

Arm description:

Subjects received 3 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 6.0 mg

Arm type	Experimental
Investigational medicinal product name	APT-1011
Investigational medicinal product code	
Other name	fluticasone propionate
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 3 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 6.0 mg

<b>Arm title</b>	Single-Blind APT-1011 3 mg BID
------------------	--------------------------------

Arm description:

Subjects received 3 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 6.0 mg

Arm type	Experimental
----------	--------------



Investigational medicinal product name	APT-1011
Investigational medicinal product code	
Other name	fluticasone propionate
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 3 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 6.0 mg

<b>Number of subjects in period 3</b>	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS
Started	10	19	14
Completed	5	17	11
Not completed	5	2	3
Consent withdrawn by subject	2	-	-
Physician decision	1	-	-
Adverse event, non-fatal	-	-	-
Other	1	-	1
Lack of efficacy	1	2	2

<b>Number of subjects in period 3</b>	APT-1011 3 mg BID	Single-Blind APT-1011 3 mg BID
Started	16	34
Completed	14	19
Not completed	2	15
Consent withdrawn by subject	-	3
Physician decision	-	-
Adverse event, non-fatal	-	1
Other	-	1
Lack of efficacy	2	10

## Baseline characteristics

### Reporting groups

Reporting group title	APT-1011 1.5 mg HS
Reporting group description:	
Subjects received placebo 30 minutes after breakfast and 1.5 mg APT-1011 HS (at bedtime) daily	
Reporting group title	APT-1011 1.5 mg BID
Reporting group description:	
Subjects received 1.5 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 3.0 mg	
Reporting group title	APT-1011 3 mg HS
Reporting group description:	
Subjects received placebo 30 minutes after breakfast and 3.0 mg APT-1011 at bedtime daily	
Reporting group title	APT-1011 3 mg BID
Reporting group description:	
Subjects received 3 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 6.0 mg	
Reporting group title	Placebo
Reporting group description:	
Subjects received placebo 30 minutes after breakfast and HS (at bedtime) daily	

Reporting group values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS
Number of subjects	21	22	21
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	21	21	20
From 65-84 years	0	1	1
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	36.8	41.3	42.9
standard deviation	± 11.65	± 12.24	± 11.52
Gender categorical			
Units: Subjects			
Female	7	7	10
Male	14	15	11
Race			
Units: Subjects			
White	21	22	20
Black or African American	0	0	1
Asian	0	0	0
American Indian or Alaska Native	0	0	0

Missing	0	0	0
Ethnicity Units: Subjects			
Hispanic or Latino	4	5	2
Not Hispanic or Latino	17	17	19
Other	0	0	0
Missing	0	0	0
Geographic Region Units: Subjects			
North America	15	16	17
Western Europe	6	6	4
Smoking status Units: Subjects			
Never	18	17	18
Former	2	3	3
Current	1	2	0
Missing	0	0	0
History of esophageal stricture(s) Units: Subjects			
Yes	11	10	8
No	10	12	13
Missing	0	0	0
Current esophageal stricture(s) based on the study EGD Units: Subjects			
Yes	4	5	5
No	17	17	16
Missing	0	0	0
History of positive steroid Response to EoE Units: Subjects			
Yes	3	5	4
No	18	17	17
Missing	0	0	0
Proton pump inhibitor status Units: Subjects			
Continuing into study	12	18	12
Not continuing into study	9	4	9
Missing	0	0	0
Height Units: cm			
arithmetic mean	175.4	173.0	170.9
standard deviation	± 8.55	± 8.56	± 9.85
Weight Units: kg			
arithmetic mean	87.4	83.7	83.6
standard deviation	± 17.69	± 14.72	± 18.89
BMI Units: kg/m2			
arithmetic mean	28.3	27.4	28.8
standard deviation	± 5.19	± 4.34	± 6.90
Global EoE Symptom Score prior to			

randomization Units: EoE Symptom Score arithmetic mean standard deviation	5.1 ± 1.62	4.5 ± 2.13	5.1 ± 1.95
<b>Reporting group values</b>	<b>APT-1011 3 mg BID</b>	<b>Placebo</b>	<b>Total</b>
Number of subjects	20	19	103
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	20	19	101
From 65-84 years	0	0	2
85 years and over	0	0	0
Age continuous Units: years arithmetic mean standard deviation	36.8 ± 9.19	38.6 ± 14.70	-
Gender categorical Units: Subjects			
Female	4	5	33
Male	16	14	70
Race Units: Subjects			
White	19	18	100
Black or African American	1	1	3
Asian	0	0	0
American Indian or Alaska Native	0	0	0
Missing	0	0	0
Ethnicity Units: Subjects			
Hispanic or Latino	2	3	16
Not Hispanic or Latino	16	16	85
Other	2	0	2
Missing	0	0	0
Geographic Region Units: Subjects			
North America	13	16	77
Western Europe	7	3	26
Smoking status Units: Subjects			
Never	16	15	84
Former	4	4	16
Current	0	0	3
Missing	0	0	0
History of esophageal stricture(s)			

Units: Subjects			
Yes	8	9	46
No	12	10	57
Missing	0	0	0
Current esophageal stricture(s) based on the study EGD			
Units: Subjects			
Yes	4	5	23
No	16	14	80
Missing	0	0	0
History of positive steroid Response to EoE			
Units: Subjects			
Yes	4	3	19
No	16	16	84
Missing	0	0	0
Proton pump inhibitor status			
Units: Subjects			
Continuing into study	13	14	69
Not continuing into study	7	5	34
Missing	0	0	0
Height			
Units: cm			
arithmetic mean	176.7	174.3	
standard deviation	± 8.61	± 7.40	-
Weight			
Units: kg			
arithmetic mean	79.7	84.1	
standard deviation	± 14.93	± 17.26	-
BMI			
Units: kg/m2			
arithmetic mean	25.5	28.4	
standard deviation	± 4.45	± 6.71	-
Global EoE Symptom Score prior to randomization			
Units: EoE Symptom Score			
arithmetic mean	4.3	5.1	
standard deviation	± 1.94	± 1.68	-

## Subject analysis sets

Subject analysis set title	Intent-to-Treat Analysis Population
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
The Intent-To-Treat (ITT) analysis population contained all subjects enrolled (All Subjects Enrolled Population) who were randomized. Subjects were classified according to randomized treatment.	
Subject analysis set title	Full Analysis Set Population
Subject analysis set type	Full analysis

Subject analysis set description:

The Full Analysis Set (FAS) analysis population contained all subjects in the ITT population who did not meet any of the following criteria:

1. Subjects who did not receive any study drug
2. Subjects given wrong drug
3. Subjects mis-randomized

Subjects were classified according to randomized treatment.

Subject analysis set title	Per-Protocol Analysis Population
Subject analysis set type	Per protocol

Subject analysis set description:

The Per-Protocol (PP) analysis population contained all subjects in the ITT analysis set who did not experience any reason for exclusion. It was used for sensitivity analysis of the primary efficacy parameter. Subjects were classified according to randomized treatment.

Subject analysis set title	Safety Analysis Population
Subject analysis set type	Safety analysis

Subject analysis set description:

The Safety Analysis Set (SAF) population contains all subjects who received at least one dose of study drug. Subjects are classified according to treatment received. If there was any doubt whether a subject was treated or not, they were assumed treated for the purposes of analysis.

Subject analysis set title	All Subjects Enrolled Population
Subject analysis set type	Intention-to-treat

Subject analysis set description:

The All Subjects Enrolled (ENR) population contained all subjects who signed an ICF.

Reporting group values	Intent-to-Treat Analysis Population	Full Analysis Set Population	Per-Protocol Analysis Population
Number of subjects	106	103	96
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	104	101	94
From 65-84 years	2	2	2
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	39.2	39.3	39.0
standard deviation	± 11.92	± 11.98	± 11.75
Gender categorical			
Units: Subjects			
Female	33	33	64
Male	73	70	32
Race			
Units: Subjects			
White	103	100	93
Black or African American	3	3	3
Asian	0	0	0
American Indian or Alaska Native	0	0	0
Missing	0	0	0
Ethnicity			
Units: Subjects			
Hispanic or Latino	16	16	13
Not Hispanic or Latino	87	85	81
Other	3	2	2

Missing	0	0	0
Geographic Region Units: Subjects			
North America	79	77	73
Western Europe	27	26	23
Smoking status Units: Subjects			
Never	87	84	77
Former	16	16	16
Current	3	3	3
Missing	0	0	0
History of esophageal stricture(s) Units: Subjects			
Yes	46	46	43
No	60	57	53
Missing	0	0	0
Current esophageal stricture(s) based on the study EGD Units: Subjects			
Yes	23	23	22
No	83	80	74
Missing	0	0	0
History of positive steroid Response to EoE Units: Subjects			
Yes	21	19	18
No	85	84	78
Missing	0	0	0
Proton pump inhibitor status Units: Subjects			
Continuing into study	71	69	64
Not continuing into study	35	34	32
Missing	0	0	0
Height Units: cm			
arithmetic mean	174.1	174.0	174.1
standard deviation	± 8.63	± 8.72	± 8.58
Weight Units: kg			
arithmetic mean	84.0	84.1	84.3
standard deviation	± 17.09	± 17.26	± 17.28
BMI Units: kg/m2			
arithmetic mean	27.6	27.7	27.7
standard deviation	± 5.57	± 5.62	± 5.69
Global EoE Symptom Score prior to randomization Units: EoE Symptom Score			
arithmetic mean	4.8	4.8	4.7
standard deviation	± 1.87	± 1.88	± 1.85

## Reporting group values

Safety Analysis  
Population

All Subjects Enrolled  
Population

Number of subjects	104	308	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	102	296	
From 65-84 years	2	12	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	39.3	41.2	
standard deviation	± 11.92	± 12.98	
Gender categorical			
Units: Subjects			
Female	33	121	
Male	71	187	
Race			
Units: Subjects			
White	101	284	
Black or African American	3	18	
Asian	0	4	
American Indian or Alaska Native	0	1	
Missing	0	1	
Ethnicity			
Units: Subjects			
Hispanic or Latino	16	42	
Not Hispanic or Latino	85	259	
Other	3	6	
Missing	0	1	
Geographic Region			
Units: Subjects			
North America	77	261	
Western Europe	27	47	
Smoking status			
Units: Subjects			
Never	85	244	
Former	16	48	
Current	3	15	
Missing	0	1	
History of esophageal stricture(s)			
Units: Subjects			
Yes	46	113	
No	58	184	
Missing	0	11	
Current esophageal stricture(s) based on the study EGD			



Units: Subjects			
Yes	23	54	
No	81	236	
Missing	0	18	
History of positive steroid Response to EoE			
Units: Subjects			
Yes	19	53	
No	85	241	
Missing	0	14	
Proton pump inhibitor status			
Units: Subjects			
Continuing into study	69	71	
Not continuing into study	35	35	
Missing	0	202	
Height			
Units: cm			
arithmetic mean	174.1	172.6	
standard deviation	± 8.69	± 9.47	
Weight			
Units: kg			
arithmetic mean	83.9	85.1	
standard deviation	± 17.24	± 19.76	
BMI			
Units: kg/m2			
arithmetic mean	27.6	28.5	
standard deviation	± 5.63	± 6.54	
Global EoE Symptom Score prior to randomization			
Units: EoE Symptom Score			
arithmetic mean	4.8	4.2	
standard deviation	± 1.87	± 2.20	

## End points

### End points reporting groups

Reporting group title	Placebo Run-in
Reporting group description: Due to the high placebo response rates, the study utilized a 4-week single-blind placebo run-in period to not only establish the baseline symptoms for the study, but also to ensure that all subjects enrolled had sufficient severity of EoE to warrant inclusion in the study.	
Reporting group title	APT-1011 1.5 mg HS
Reporting group description: Subjects received placebo 30 minutes after breakfast and 1.5 mg APT-1011 HS (at bedtime) daily	
Reporting group title	APT-1011 1.5 mg BID
Reporting group description: Subjects received 1.5 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 3.0 mg	
Reporting group title	APT-1011 3 mg HS
Reporting group description: Subjects received placebo 30 minutes after breakfast and 3.0 mg APT-1011 at bedtime daily	
Reporting group title	APT-1011 3 mg BID
Reporting group description: Subjects received 3 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 6.0 mg	
Reporting group title	Placebo
Reporting group description: Subjects received placebo 30 minutes after breakfast and HS (at bedtime) daily	
Reporting group title	APT-1011 1.5 mg HS
Reporting group description: Subjects received placebo 30 minutes after breakfast and 1.5 mg APT-1011 HS (at bedtime) daily	
Reporting group title	APT-1011 1.5 mg BID
Reporting group description: Subjects received 1.5 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 3.0 mg	
Reporting group title	APT-1011 3 mg HS
Reporting group description: Subjects received placebo 30 minutes after breakfast and 3.0 mg APT-1011 at bedtime daily	
Reporting group title	APT-1011 3 mg BID
Reporting group description: Subjects received 3 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 6.0 mg	
Reporting group title	Single-Blind APT-1011 3 mg BID
Reporting group description: Subjects received 3 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 6.0 mg	
Subject analysis set title	Intent-to-Treat Analysis Population
Subject analysis set type	Intention-to-treat
Subject analysis set description: The Intent-To-Treat (ITT) analysis population contained all subjects enrolled (All Subjects Enrolled Population) who were randomized. Subjects were classified according to randomized treatment.	
Subject analysis set title	Full Analysis Set Population
Subject analysis set type	Full analysis
Subject analysis set description: The Full Analysis Set (FAS) analysis population contained all subjects in the ITT population who did not meet any of the following criteria: 1. Subjects who did not receive any study drug	

2. Subjects given wrong drug

3. Subjects mis-randomized

Subjects were classified according to randomized treatment.

Subject analysis set title	Per-Protocol Analysis Population
Subject analysis set type	Per protocol

Subject analysis set description:

The Per-Protocol (PP) analysis population contained all subjects in the ITT analysis set who did not experience any reason for exclusion. It was used for sensitivity analysis of the primary efficacy parameter. Subjects were classified according to randomized treatment.

Subject analysis set title	Safety Analysis Population
Subject analysis set type	Safety analysis

Subject analysis set description:

The Safety Analysis Set (SAF) population contains all subjects who received at least one dose of study drug. Subjects are classified according to treatment received. If there was any doubt whether a subject was treated or not, they were assumed treated for the purposes of analysis.

Subject analysis set title	All Subjects Enrolled Population
Subject analysis set type	Intention-to-treat

Subject analysis set description:

The All Subjects Enrolled (ENR) population contained all subjects who signed an ICF.

### Primary: Percentage of subjects with $\leq 6$ peak eos/HPF

End point title	Percentage of subjects with $\leq 6$ peak eos/HPF
-----------------	---

End point description:

Percentage of subjects with  $\leq 6$  peak eosinophils (eos)/high-power field (HPF) after assessing at least 5 to 6 biopsies from the proximal and distal esophagus (approximately 3 each) where the HPF area was 235 square microns (40 magnification lens with a 22 mm ocular)

End point type	Primary
----------------	---------

End point timeframe:

Week 12

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Number of Patients				
Responder	10	19	14	16
Non-Responder	11	3	7	4

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Number of Patients				
Responder	0			
Non-Responder	19			

## Statistical analyses

<b>Statistical analysis title</b>	Histology: 1.5 mg HS to Placebo
Comparison groups	APT-1011 1.5 mg HS v Placebo
Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Confidence interval	
level	90 %
sides	2-sided
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	Histology: 1.5 mg BID to Placebo
Comparison groups	APT-1011 1.5 mg BID v Placebo
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Confidence interval	
level	90 %
sides	2-sided
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	Histology: 3 mg HS to Placebo
Comparison groups	APT-1011 3 mg HS v Placebo
Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Confidence interval	
level	90 %
sides	2-sided
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	Histology: 3 mg BID to Placebo
Comparison groups	APT-1011 3 mg BID v Placebo

Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Confidence interval	
level	90 %
sides	2-sided
Variability estimate	Standard deviation

### Secondary: Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52

End point title	Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52
-----------------	---

End point description:

Percentage of subjects who met the primary endpoint (histology) at Week 12 and maintained the primary endpoint at Weeks 26 and 52

Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect percentage of subjects who met the primary endpoint following 12 or 38 weeks of treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 26, and Week 52

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	19	14	16
Units: Percentage of participants				
Week 26 Responders	7	17	11	14
Week 52 Responders	3	16	9	11

End point values	Placebo	Single-Blind APT-1011 3 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	16	18		
Units: Percentage of participants				
Week 26 Responders	12	7		
Week 52 Responders	10	5		

### Statistical analyses

**Secondary: Change from Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Weeks 12, 26, and 52**

End point title	Change from Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Weeks 12, 26, and 52
End point description:	
Endoscopic changes will be assessed as per the EREFs evaluation based on the following endoscopic features: edema, rings, exudates, furrows, stricture, and several miscellaneous features (crepe paper esophagus, narrow caliber esophagus, and esophageal erosions). Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect EREF evaluation following 12 or 38 weeks of treatment.	
End point type	Secondary
End point timeframe:	
Week 12, Week 26, and Week 52	

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: mean change				
arithmetic mean (standard deviation)				
Week 12 (n=18, n=20, n=20, n=19, n=17)	-2.4 (± 2.04)	-2.7 (± 2.66)	-3.3 (± 2.36)	-2.2 (± 2.15)
Week 26 (n=8, n=19, n=13, n=16, n=0)	-3.1 (± 1.25)	-3.2 (± 2.77)	-4.2 (± 2.61)	-3.0 (± 1.67)
Week 52 (n=5, n=17, n=11, n=14, n=0)	-3.4 (± 1.82)	-3.5 (± 3.08)	-3.8 (± 3.19)	-2.9 (± 1.29)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: mean change				
arithmetic mean (standard deviation)				
Week 12 (n=18, n=20, n=20, n=19, n=17)	-0.9 (± 1.63)			
Week 26 (n=8, n=19, n=13, n=16, n=0)	0 (± 0)			
Week 52 (n=5, n=17, n=11, n=14, n=0)	0 (± 0)			

**Statistical analyses**

Statistical analysis title	Change from Baseline EREFs: 1.5 mg HS to Placebo
Comparison groups	APT-1011 1.5 mg HS v Placebo

Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.02
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	-1.28
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.29
upper limit	-0.26
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	Change from Baseline EREFs: 1.5 mg BID to Placebo
Comparison groups	APT-1011 1.5 mg BID v Placebo
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	-2.08
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.07
upper limit	-1.1
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	Change from Baseline EREFs: 3.0 mg HS to Placebo
Comparison groups	APT-1011 3 mg HS v Placebo
Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	-2.25
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.23
upper limit	-1.26
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	Change from Baseline EREFs: 3 mg BID to Placebo
Comparison groups	APT-1011 3 mg BID v Placebo
Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.005
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	-1.59
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.59
upper limit	-0.59
Variability estimate	Standard deviation

### Secondary: Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15

End point title	Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15
End point description:	
Peak eosinophils/high power field (HPF) number <1 and <15 at Weeks 12, 26 and 52	
Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect peak eosinophils/HPF following 12 or 38 weeks of treatment.	
End point type	Secondary
End point timeframe:	
Week 12, Week 26, Week 52	

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Percentage of Participants				
number (not applicable)				
Week 12 <1/HPF	38.9	70.0	60.0	78.9
Week 12 <15 HPF	66.7	95.0	75.0	84.2
Week 26 <1/HPF	50.0	78.9	69.2	81.3
Week 26 <15/HPF	100.0	94.7	92.3	87.5
Week 52 <1/HPF	20.0	70.6	63.6	71.4
Week 52 <15/HPF	60.0	100.0	90.9	85.7



End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Percentage of Participants				
number (not applicable)				
Week 12 <1/HPF	0			
Week 12 <15 HPF	5.9			
Week 26 <1/HPF	0			
Week 26 <15/HPF	0			
Week 52 <1/HPF	0			
Week 52 <15/HPF	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline Global EOE Symptom Score

End point title	Change From Baseline Global EOE Symptom Score
End point description:	
Change from Baseline Global EOE Symptom Score Assessed Prior to Randomization	
Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline global EOE symptom score following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment.	
End point type	Secondary
End point timeframe:	
Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, 52	

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Mean				
arithmetic mean (standard deviation)				
Week 4 (n=21, n=20, n=20, n=20, n=16)	-1.8 (± 2.64)	-1.3 (± 2.15)	-2.5 (± 3.12)	-1.6 (± 1.39)
Week 8 (n=18, n=22, n=19, n=20, n=17)	-2.6 (± 2.12)	-1.7 (± 1.94)	-3.1 (± 2.64)	-2.1 (± 1.92)
Week 12 (n=18, n=21, n=20, n=19, n=17)	-3.1 (± 2.17)	-1.5 (± 2.20)	-3.1 (± 2.74)	-1.7 (± 2.42)
Week 14 (n=10, n=18, n=13, n=16, n=0)	-2.7 (± 2.26)	-2.3 (± 2.45)	-3.9 (± 2.81)	-2.8 (± 1.77)
Week 18 (n=9, n=19, n=14, n=15, n=0)	-4.1 (± 1.36)	-2.7 (± 2.58)	-4.1 (± 2.92)	-3.1 (± 2.17)
Week 22 (n=8, n=19, n=14, n=16, n=0)	-4.0 (± 1.41)	-3.2 (± 2.46)	-3.8 (± 2.97)	-3.0 (± 2.76)
Week 26 (n=8, n=18, n=13, n=16, n=0)	-3.8 (± 1.39)	-3.1 (± 2.52)	-4.0 (± 2.68)	-3.8 (± 2.57)
Week 28 (n=7, n=18, n=10, n=14 n=0)	-4.3 (± 1.38)	-3.3 (± 2.42)	-4.8 (± 2.44)	-3.9 (± 2.09)

Week 36 (n=6, n=16, n=11, n=14, n=0)	-4.2 (± 1.47)	-3.9 (± 2.25)	-4.8 (± 2.09)	-3.9 (± 2.07)
Week 44 (n=5, n=15, n=11, n=14, n=0)	-4.8 (± 2.39)	-3.7 (± 2.41)	-4.4 (± 3.20)	-4.4 (± 1.95)
Week 52 (n=4, n=14, n=10, n=14, n=0)	-3.3 (± 1.71)	-3.1 (± 2.40)	-4.2 (± 2.66)	-4.7 (± 2.27)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Mean				
arithmetic mean (standard deviation)				
Week 4 (n=21, n=20, n=20, n=20, n=16)	-1.0 (± 1.67)			
Week 8 (n=18, n=22, n=19, n=20, n=17)	-1.4 (± 2.21)			
Week 12 (n=18, n=21, n=20, n=19, n=17)	-1.7 (± 1.83)			
Week 14 (n=10, n=18, n=13, n=16, n=0)	0 (± 0)			
Week 18 (n=9, n=19, n=14, n=15, n=0)	0 (± 0)			
Week 22 (n=8, n=19, n=14, n=16, n=0)	0 (± 0)			
Week 26 (n=8, n=18, n=13, n=16, n=0)	0 (± 0)			
Week 28 (n=7, n=18, n=10, n=14 n=0)	0 (± 0)			
Week 36 (n=6, n=16, n=11, n=14, n=0)	0 (± 0)			
Week 44 (n=5, n=15, n=11, n=14, n=0)	0 (± 0)			
Week 52 (n=4, n=14, n=10, n=14, n=0)	0 (± 0)			

## Statistical analyses

<b>Statistical analysis title</b>	CFB Week 12: 1.5 mg HS to Placebo
Comparison groups	APT-1011 1.5 mg HS v Placebo
Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.067
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	-1.19
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.49
upper limit	0.12

Variability estimate	Standard deviation
----------------------	--------------------

  

<b>Statistical analysis title</b>	CFB Week 12: 1.5 mg BID to Placebo
Comparison groups	APT-1011 1.5 mg BID v Placebo
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.672
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	0.34
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.91
upper limit	1.59
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	CFB Week 12: 3 mg HS to Placebo
Comparison groups	Placebo v APT-1011 3 mg HS
Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.048
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	-1.28
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.55
upper limit	-0.01
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	CFB Week 12: 3 mg BID to Placebo
Comparison groups	Placebo v APT-1011 3 mg BID
Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.653
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	0.31

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.98
upper limit	1.59
Variability estimate	Standard deviation

## Secondary: Change in the Number of Dysphagia Episodes

End point title	Change in the Number of Dysphagia Episodes
End point description:	
Change in the number of dysphagia episodes at baseline (14-day period prior to randomization) compared with the 14-day period prior to the timepoint of interest	
Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect the change in the number of dysphagia episodes following 12 or 38 weeks of treatment.	
End point type	Secondary
End point timeframe:	
Weeks, 12, 26 and 52	

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: mean change from baseline				
arithmetic mean (standard deviation)				
CFB Week 12 (n=18, n=21, n=20, n=19, n=17)	-8.2 (± 5.48)	-4.4 (± 9.41)	-9.3 (± 7.37)	-9.1 (± 11.01)
CFB Week 26 (n=8, n=19, n=13, n=15, n=0)	-12.8 (± 5.65)	-10.0 (± 10.97)	-9.8 (± 7.82)	-13.4 (± 11.78)
CFB Week 52 (n=5, n=16, n=10, n=14, n=0)	-11.2 (± 5.26)	-13.0 (± 10.79)	-9.5 (± 9.66)	-14.5 (± 11.68)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: mean change from baseline				
arithmetic mean (standard deviation)				
CFB Week 12 (n=18, n=21, n=20, n=19, n=17)	-5.5 (± 7.89)			
CFB Week 26 (n=8, n=19, n=13, n=15, n=0)	0 (± 0)			
CFB Week 52 (n=5, n=16, n=10, n=14, n=0)	0 (± 0)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score

End point title	Change from Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score
-----------------	--

End point description:

Change from Baseline 7-Day 7-day Eosinophilic Esophagitis Activity Index (EEsAI) total score assessed prior to randomization and those assessed at Weeks 12, 26 and 52 (Total score 100)

Components of the EEsAI were also reported: Avoidance, Modification and Slow Eating (AMS) Score, minimum 0, maximum 10; and Visual Dysphagia Question (VDQ) Score, minimum 0, maximum 10. Higher score means a worse outcome

Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect the change from baseline 7-day EEsAI total score following 12 or 38 weeks of treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 12, 26 and 52

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Mean Change from Baseline arithmetic mean (standard deviation)				
EEsAI Week 12 (n=18, n=20, n=20, n=19, n=17)	-20.4 (± 15.90)	-15.6 (± 21.02)	-22.7 (± 16.60)	-22.6 (± 21.11)
EEsAI Week 26 (n=8, n=19, n=13, n=16, n=0)	-25.6 (± 21.11)	-29.6 (± 25.48)	-28.8 (± 21.10)	-34.6 (± 25.43)
EEsAI Week 52 (n=5, n=17, n=11, n=14, n=0)	-39.8 (± 28.42)	-37.4 (± 27.02)	-37.0 (± 23.72)	-41.1 (± 20.56)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Mean Change from Baseline arithmetic mean (standard deviation)				
EEsAI Week 12 (n=18, n=20, n=20, n=19, n=17)	-9.6 (± 14.07)			
EEsAI Week 26 (n=8, n=19, n=13, n=16, n=0)	0 (± 0)			
EEsAI Week 52 (n=5, n=17, n=11, n=14, n=0)	0 (± 0)			

## Statistical analyses

<b>Statistical analysis title</b>	EEsAI Total Score Change from Baseline Week 12
Comparison groups	APT-1011 1.5 mg HS v Placebo
Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.071
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-8.81
Confidence interval	
level	90 %
sides	2-sided
lower limit	-19.36
upper limit	1.13
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	EEsAI Total Score Change from Baseline Week 12
Comparison groups	APT-1011 1.5 mg BID v Placebo
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.217
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-5.18
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14.72
upper limit	5.28
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	EEsAI Total Score Change from Baseline Week 12
Comparison groups	APT-1011 3 mg HS v Placebo
Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.016
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-12.56
Confidence interval	
level	90 %
sides	2-sided
lower limit	-23.04
upper limit	-3.05

Variability estimate	Standard deviation
<b>Statistical analysis title</b>	EEsAI Total Score Change from Baseline Week 12
Comparison groups	Placebo v APT-1011 3 mg BID
Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.05
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-10.61
Confidence interval	
level	90 %
sides	2-sided
lower limit	-20.4
upper limit	0.02
Variability estimate	Standard deviation

### Secondary: Percentage of subjects with mean 7-day EEsAI total score <20

End point title	Percentage of subjects with mean 7-day EEsAI total score <20
End point description:	
Percentage of subjects with mean 7-day EEsAI total score <20 to those assessed at Weeks 12, 26, and 52	
Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline global EOE symptom score following 12 or 38 weeks of treatment.	
End point type	Secondary
End point timeframe:	
Weeks 12, 26, and 52	

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Percentage of Participants				
number (not applicable)				
Week 12 (n=18, n=20, n=20, n=19, n=17)	22.2	5.0	30.0	26.3
Week 26 (n=8, n=19, n=13, n=16, n=0)	37.5	26.3	53.8	43.8
Week 52 (n=5, n=17, n=11, n=14, n=0)	60.0	41.2	63.6	71.4

End point values	Placebo			
------------------	---------	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Percentage of Participants				
number (not applicable)				
Week 12 (n=18, n=20, n=20, n=19, n=17)	11.8			
Week 26 (n=8, n=19, n=13, n=16, n=0)	0			
Week 52 (n=5, n=17, n=11, n=14, n=0)	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change in Patient Global Impression of Severity (PGIS) for EoE Symptoms

End point title	Change in Patient Global Impression of Severity (PGIS) for EoE Symptoms
-----------------	---

End point description:

Change From Baseline PGIS for EoE Symptoms as Assessed Prior to Randomization at Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52

Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline global EOE symptom score following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks, 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Percentage of participants				
Week 4 Mild to None (n=20, n=19, n=20, n=19, n=15)	1	0	0	0
Week 4 Mild to Mild	0	0	1	0
Week 4 Mild to Moderate	0	0	0	0
Week 4 Mild to Severe	1	0	0	0
Week 4 Mild to Very Severe	0	0	0	0
Week 4 Moderate to None	0	0	4	0
Week 4 Moderate to Mild	8	7	5	6
Week 4 Moderate to Moderate	5	5	4	7
Week 4 Moderate to Severe	0	0	0	1
Week 4 Moderate to Very Severe	0	0	0	0
Week 4 Severe to None	0	0	1	0
Week 4 Severe to Mild	3	1	1	1
Week 4 Severe to Moderate	1	3	3	4



Week 4 Severe to Severe	0	3	1	0
Week 4 Severe to Very Severe	0	0	0	0
Week 4 Very Severe to None	0	0	0	0
Week 4 Very Severe to Mild	0	0	0	0
Week 4 Very Severe to Moderate	0	0	0	0
Week 4 Very Severe to Severe	0	0	0	0
Week 4 Very Severe to Very Severe	1	0	0	0
Week 8 Mild to None (n=17, n=21, n=19, n=19, n=16)	0	0	0	0
Week 8 Mild to Mild	0	0	1	0
Week 8 Mild to Moderate	1	0	0	0
Week 8 Mild to Severe	0	0	0	0
Week 8 Mild to Very Severe	0	0	0	0
Week 8 Moderate to None	1	1	4	2
Week 8 Moderate to Mild	8	6	5	6
Week 8 Moderate to Moderate	3	6	3	6
Week 8 Moderate to Severe	0	0	0	0
Week 8 Moderate to Very Severe	0	0	0	0
Week 8 Severe to None	1	0	1	1
Week 8 Severe to Mild	1	1	2	0
Week 8 Severe to Moderate	1	6	1	4
Week 8 Severe to Severe	0	1	2	0
Week 8 Severe to Very Severe	0	0	0	0
Week 8 Very Severe to None	0	0	0	0
Week 8 Very Severe to Mild	0	0	0	0
Week 8 Very Severe to Moderate	0	0	0	0
Week 8 Very Severe to Severe	1	0	0	0
Week 8 Very Severe to Very Severe	0	0	0	0
Week 12 Mild to None (n=18, n=20, n=20, n=18,n=17)	0	0	0	0
Week 12 Mild to Mild	1	0	1	0
Week 12 Mild to Moderate	0	0	0	0
Week 12 Mild to Severe	0	0	0	0
Week 12 Mild to Very Severe	0	0	0	0
Week 12 Moderate to None	1	0	5	2
Week 12 Moderate to Mild	10	7	5	6
Week 12 Moderate to Moderate	2	5	3	4
Week 12 Moderate to Severe	0	0	0	1
Week 12 Moderate to Very Severe	0	0	0	0
Week 12 Severe to None	2	0	1	1
Week 12 Severe to Mild	1	3	0	1
Week 12 Severe to Moderate	0	4	4	2
Week 12 Severe to Severe	0	1	1	1
Week 12 Severe to Very Severe	0	0	0	0
Week 12 Very Severe to None	0	0	0	0
Week 12 Very Severe to Mild	0	0	0	0
Week 12 Very Severe to Moderate	1	0	0	0
Week 12 Very Severe to Severe	0	0	0	0
Week 12 Very Severe to Very Severe	0	0	0	0
Week 14 Mild to None (n=10, n=18, n=13, n=15, n=0)	0	0	0	0
Week 14 Mild to Mild	1	0	1	0
Week 14 Mild to Moderate	0	0	0	0

Week 14 Mild to Severe	0	0	0	0
Week 14 Mild to Very Severe	0	0	0	0
Week 14 Moderate to None	0	1	5	4
Week 14 Moderate to Mild	7	8	1	3
Week 14 Moderate to Moderate	0	2	1	4
Week 14 Moderate to Severe	0	0	0	0
Week 14 Moderate to Very Severe	0	0	0	0
Week 14 Severe to None	0	1	0	1
Week 14 Severe to Mild	1	1	3	1
Week 14 Severe to Moderate	0	5	1	2
Week 14 Severe to Severe	0	0	1	0
Week 14 Severe to Very Severe	0	0	0	0
Week 14 Very Severe to None	0	0	0	0
Week 14 Very Severe to Mild	0	0	0	0
Week 14 Very Severe to Moderate	0	0	0	0
Week 14 Very Severe to Severe	0	0	0	0
Week 14 Very Severe to Very Severe	1	0	0	0
Week 18 Mild to None (n=9, n=18, n=14, n=14, n=0)	0	0	0	0
Week 18 Mild to Mild	0	0	1	0
Week 18 Mild to Moderate	0	0	0	0
Week 18 Mild to Severe	0	0	0	0
Week 18 Mild to Very Severe	0	0	0	0
Week 18 Moderate to None	0	1	5	5
Week 18 Moderate to Mild	6	9	2	4
Week 18 Moderate to Moderate	1	1	1	2
Week 18 Moderate to Severe	0	0	0	0
Week 18 Moderate to Very Severe	0	0	0	0
Week 18 Severe to None	0	2	1	0
Week 18 Severe to Mild	1	2	2	1
Week 18 Severe to Moderate	0	3	1	2
Week 18 Severe to Severe	0	0	1	0
Week 18 Severe to Very Severe	0	0	0	0
Week 18 Very Severe to None	0	0	0	0
Week 18 Very Severe to Mild	0	0	0	0
Week 18 Very Severe to Moderate	1	0	0	0
Week 18 Very Severe to Severe	0	0	0	0
Week 18 Very Severe to Very Severe	0	0	0	0
Week 22 Mild to None (n=8, n=18, n=13, n=16, n=0)	0	0	0	0
Week 22 Mild to Mild	0	0	1	0
Week 22 Mild to Moderate	0	0	0	0
Week 22 Mild to Severe	0	0	0	0
Week 22 Mild to Very Severe	0	0	0	0
Week 22 Moderate to None	1	2	3	4
Week 22 Moderate to Mild	6	8	2	3
Week 22 Moderate to Moderate	0	1	2	5
Week 22 Moderate to Severe	0	0	0	0
Week 22 Moderate to Very Severe	0	0	0	0
Week 22 Severe to None	0	1	1	2
Week 22 Severe to Mild	1	3	1	0
Week 22 Severe to Moderate	0	2	2	2

Week 22 Severe to Severe	0	1	0	0
Week 22 Severe to Very Severe	0	0	1	0
Week 22 Very Severe to None	0	0	0	0
Week 22 Very Severe to Mild	0	0	0	0
Week 22 Very Severe to Moderate	0	0	0	0
Week 22 Very Severe to Severe	0	0	0	0
Week 22 Very Severe to Very Severe	0	0	0	0
Week 26 Mild to None (n=8, n=17, n=13, n=16, n=0)	0	0	0	0
Week 26 Mild to Mild	0	0	1	0
Week 26 Mild to Moderate	0	0	0	0
Week 26 Mild to Severe	0	0	0	0
Week 26 Mild to Very Severe	0	0	0	0
Week 26 Moderate to None	2	1	4	5
Week 26 Moderate to Mild	2	8	2	5
Week 26 Moderate to Moderate	2	2	1	2
Week 26 Moderate to Severe	0	0	0	0
Week 26 Moderate to Very Severe	0	0	0	0
Week 26 Severe to None	0	2	2	1
Week 26 Severe to Mild	1	2	2	2
Week 26 Severe to Moderate	0	2	0	1
Week 26 Severe to Severe	0	0	1	0
Week 26 Severe to Very Severe	0	0	0	0
Week 26 Very Severe to None	0	0	0	0
Week 26 Very Severe to Mild	0	0	0	0
Week 26 Very Severe to Moderate	1	0	0	0
Week 26 Very Severe to Severe	0	0	0	0
Week 26 Very Severe to Very Severe	0	0	0	0
Week 28 Mild to None (n=7, n=16, n=10, n=14, n=0)	0	0	0	0
Week 28 Mild to Mild	0	0	1	0
Week 28 Mild to Moderate	0	0	0	0
Week 28 Mild to Severe	0	0	0	0
Week 28 Mild to Very Severe	0	0	0	0
Week 28 Moderate to None	2	1	4	4
Week 28 Moderate to Mild	3	7	1	5
Week 28 Moderate to Moderate	0	2	0	1
Week 28 Moderate to Severe	0	0	0	0
Week 28 Moderate to Very Severe	0	0	0	0
Week 28 Severe to None	0	2	2	1
Week 28 Severe to Mild	1	2	0	3
Week 28 Severe to Moderate	0	2	1	0
Week 28 Severe to Severe	0	0	1	0
Week 28 Severe to Very Severe	0	0	0	0
Week 28 Very Severe to None	0	0	0	0
Week 28 Very Severe to Mild	1	0	0	0
Week 28 Very Severe to Moderate	0	0	0	0
Week 28 Very Severe to Severe	0	0	0	0
Week 28 Very Severe to Very Severe	0	0	0	0
Week 36 Mild to None (n=6, n=15, n=11, n=14, n=0)	0	0	0	0
Week 36 Mild to Mild	0	0	1	0
Week 36 Mild to Moderate	0	0	0	0

Week 36 Mild to Severe	0	0	0	0
Week 36 Mild to Very Severe	0	0	0	0
Week 36 Moderate to None	0	2	5	4
Week 36 Moderate to Mild	4	7	1	5
Week 36 Moderate to Moderate	0	1	0	1
Week 36 Moderate to Severe	0	0	0	0
Week 36 Moderate to Very Severe	0	0	0	0
Week 36 Severe to None	0	3	2	1
Week 36 Severe to Mild	1	2	1	2
Week 36 Severe to Moderate	0	0	0	1
Week 36 Severe to Severe	0	0	0	0
Week 36 Severe to Very Severe	0	0	1	0
Week 36 Very Severe to None	0	0	0	0
Week 36 Very Severe to Mild	0	0	0	0
Week 36 Very Severe to Moderate	1	0	0	0
Week 36 Very Severe to Severe	0	0	0	0
Week 36 Very Severe to Very Severe	0	0	0	0
Week 44 Mild to None (n=5, n=15, n=10, n=14, n=0)	0	0	0	0
Week 44 Mild to Mild	0	0	1	0
Week 44 Mild to Moderate	0	0	0	0
Week 44 Mild to Severe	0	0	0	0
Week 44 Mild to Very Severe	0	0	0	0
Week 44 Moderate to None	1	1	3	5
Week 44 Moderate to Mild	2	8	1	4
Week 44 Moderate to Moderate	0	1	1	1
Week 44 Moderate to Severe	0	0	0	0
Week 44 Moderate to Very Severe	0	0	0	0
Week 44 Severe to None	0	3	2	2
Week 44 Severe to Mild	1	2	1	1
Week 44 Severe to Moderate	0	0	0	1
Week 44 Severe to Severe	0	0	0	0
Week 44 Severe to Very Severe	0	0	1	0
Week 44 Very Severe to None	0	0	0	0
Week 44 Very Severe to Mild	1	0	0	0
Week 44 Very Severe to Moderate	0	0	0	0
Week 44 Very Severe to Severe	0	0	0	0
Week 44 Very Severe to Very Severe	0	0	0	0
Week 52 Mild to None (n=4, n=14, n=10, n=14, n=0)	0	0	1	0
Week 52 Mild to Mild	0	0	0	0
Week 52 Mild to Moderate	0	0	0	0
Week 52 Mild to Severe	0	0	0	0
Week 52 Mild to Very Severe	0	0	0	0
Week 52 Moderate to None	0	3	5	8
Week 52 Moderate to Mild	3	3	1	1
Week 52 Moderate to Moderate	0	4	0	1
Week 52 Moderate to Severe	0	0	0	0
Week 52 Moderate to Very Severe	0	0	0	0
Week 52 Severe to None	0	3	1	3
Week 52 Severe to Mild	0	1	1	0
Week 52 Severe to Moderate	1	0	0	1

Week 52 Severe to Severe	0	0	0	0
Week 52 Severe to Very Severe	0	0	1	0
Week 52 Very Severe to None	0	0	0	0
Week 52 Very Severe to Mild	0	0	0	0
Week 52 Very Severe to Moderate	0	0	0	0
Week 52 Very Severe to Severe	0	0	0	0
Week 52 Very Severe to Very Severe	0	0	0	0

<b>End point values</b>	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Percentage of participants				
Week 4 Mild to None (n=20, n=19, n=20, n=19, n=15)	1			
Week 4 Mild to Mild	0			
Week 4 Mild to Moderate	0			
Week 4 Mild to Severe	0			
Week 4 Mild to Very Severe	0			
Week 4 Moderate to None	1			
Week 4 Moderate to Mild	5			
Week 4 Moderate to Moderate	3			
Week 4 Moderate to Severe	0			
Week 4 Moderate to Very Severe	0			
Week 4 Severe to None	0			
Week 4 Severe to Mild	0			
Week 4 Severe to Moderate	2			
Week 4 Severe to Severe	3			
Week 4 Severe to Very Severe	0			
Week 4 Very Severe to None	0			
Week 4 Very Severe to Mild	0			
Week 4 Very Severe to Moderate	0			
Week 4 Very Severe to Severe	0			
Week 4 Very Severe to Very Severe	0			
Week 8 Mild to None (n=17, n=21, n=19, n=19, n=16)	0			
Week 8 Mild to Mild	1			
Week 8 Mild to Moderate	0			
Week 8 Mild to Severe	0			
Week 8 Mild to Very Severe	0			
Week 8 Moderate to None	1			
Week 8 Moderate to Mild	7			
Week 8 Moderate to Moderate	2			
Week 8 Moderate to Severe	0			
Week 8 Moderate to Very Severe	0			
Week 8 Severe to None	0			
Week 8 Severe to Mild	0			
Week 8 Severe to Moderate	5			
Week 8 Severe to Severe	0			
Week 8 Severe to Very Severe	0			

Week 8 Very Severe to None	0			
Week 8 Very Severe to Mild	0			
Week 8 Very Severe to Moderate	0			
Week 8 Very Severe to Severe	0			
Week 8 Very Severe to Very Severe	0			
Week 12 Mild to None (n=18, n=20, n=20, n=18,n=17)	1			
Week 12 Mild to Mild	0			
Week 12 Mild to Moderate	0			
Week 12 Mild to Severe	0			
Week 12 Mild to Very Severe	0			
Week 12 Moderate to None	1			
Week 12 Moderate to Mild	6			
Week 12 Moderate to Moderate	3			
Week 12 Moderate to Severe	0			
Week 12 Moderate to Very Severe	0			
Week 12 Severe to None	0			
Week 12 Severe to Mild	1			
Week 12 Severe to Moderate	4			
Week 12 Severe to Severe	1			
Week 12 Severe to Very Severe	0			
Week 12 Very Severe to None	0			
Week 12 Very Severe to Mild	0			
Week 12 Very Severe to Moderate	0			
Week 12 Very Severe to Severe	0			
Week 12 Very Severe to Very Severe	0			
Week 14 Mild to None (n=10, n=18, n=13, n=15, n=0)	0			
Week 14 Mild to Mild	0			
Week 14 Mild to Moderate	0			
Week 14 Mild to Severe	0			
Week 14 Mild to Very Severe	0			
Week 14 Moderate to None	0			
Week 14 Moderate to Mild	0			
Week 14 Moderate to Moderate	0			
Week 14 Moderate to Severe	0			
Week 14 Moderate to Very Severe	0			
Week 14 Severe to None	0			
Week 14 Severe to Mild	0			
Week 14 Severe to Moderate	0			
Week 14 Severe to Severe	0			
Week 14 Severe to Very Severe	0			
Week 14 Very Severe to None	0			
Week 14 Very Severe to Mild	0			
Week 14 Very Severe to Moderate	0			
Week 14 Very Severe to Severe	0			
Week 14 Very Severe to Very Severe	0			
Week 18 Mild to None (n=9, n=18, n=14, n=14, n=0)	0			
Week 18 Mild to Mild	0			
Week 18 Mild to Moderate	0			
Week 18 Mild to Severe	0			
Week 18 Mild to Very Severe	0			

Week 18 Moderate to None	0			
Week 18 Moderate to Mild	0			
Week 18 Moderate to Moderate	0			
Week 18 Moderate to Severe	0			
Week 18 Moderate to Very Severe	0			
Week 18 Severe to None	0			
Week 18 Severe to Mild	0			
Week 18 Severe to Moderate	0			
Week 18 Severe to Severe	0			
Week 18 Severe to Very Severe	0			
Week 18 Very Severe to None	0			
Week 18 Very Severe to Mild	0			
Week 18 Very Severe to Moderate	0			
Week 18 Very Severe to Severe	0			
Week 18 Very Severe to Very Severe	0			
Week 22 Mild to None (n=8, n=18, n=13, n=16, n=0)	0			
Week 22 Mild to Mild	0			
Week 22 Mild to Moderate	0			
Week 22 Mild to Severe	0			
Week 22 Mild to Very Severe	0			
Week 22 Moderate to None	0			
Week 22 Moderate to Mild	0			
Week 22 Moderate to Moderate	0			
Week 22 Moderate to Severe	0			
Week 22 Moderate to Very Severe	0			
Week 22 Severe to None	0			
Week 22 Severe to Mild	0			
Week 22 Severe to Moderate	0			
Week 22 Severe to Severe	0			
Week 22 Severe to Very Severe	0			
Week 22 Very Severe to None	0			
Week 22 Very Severe to Mild	0			
Week 22 Very Severe to Moderate	0			
Week 22 Very Severe to Severe	0			
Week 22 Very Severe to Very Severe	0			
Week 26 Mild to None (n=8, n=17, n=13, n=16, n=0)	0			
Week 26 Mild to Mild	0			
Week 26 Mild to Moderate	0			
Week 26 Mild to Severe	0			
Week 26 Mild to Very Severe	0			
Week 26 Moderate to None	0			
Week 26 Moderate to Mild	0			
Week 26 Moderate to Moderate	0			
Week 26 Moderate to Severe	0			
Week 26 Moderate to Very Severe	0			
Week 26 Severe to None	0			
Week 26 Severe to Mild	0			
Week 26 Severe to Moderate	0			
Week 26 Severe to Severe	0			
Week 26 Severe to Very Severe	0			

Week 26 Very Severe to None	0			
Week 26 Very Severe to Mild	0			
Week 26 Very Severe to Moderate	0			
Week 26 Very Severe to Severe	0			
Week 26 Very Severe to Very Severe	0			
Week 28 Mild to None (n=7, n=16, n=10, n=14, n=0)	0			
Week 28 Mild to Mild	0			
Week 28 Mild to Moderate	0			
Week 28 Mild to Severe	0			
Week 28 Mild to Very Severe	0			
Week 28 Moderate to None	0			
Week 28 Moderate to Mild	0			
Week 28 Moderate to Moderate	0			
Week 28 Moderate to Severe	0			
Week 28 Moderate to Very Severe	0			
Week 28 Severe to None	0			
Week 28 Severe to Mild	0			
Week 28 Severe to Moderate	0			
Week 28 Severe to Severe	0			
Week 28 Severe to Very Severe	0			
Week 28 Very Severe to None	0			
Week 28 Very Severe to Mild	0			
Week 28 Very Severe to Moderate	0			
Week 28 Very Severe to Severe	0			
Week 28 Very Severe to Very Severe	0			
Week 36 Mild to None (n=6, n=15, n=11, n=14, n=0)	0			
Week 36 Mild to Mild	0			
Week 36 Mild to Moderate	0			
Week 36 Mild to Severe	0			
Week 36 Mild to Very Severe	0			
Week 36 Moderate to None	0			
Week 36 Moderate to Mild	0			
Week 36 Moderate to Moderate	0			
Week 36 Moderate to Severe	0			
Week 36 Moderate to Very Severe	0			
Week 36 Severe to None	0			
Week 36 Severe to Mild	0			
Week 36 Severe to Moderate	0			
Week 36 Severe to Severe	0			
Week 36 Severe to Very Severe	0			
Week 36 Very Severe to None	0			
Week 36 Very Severe to Mild	0			
Week 36 Very Severe to Moderate	0			
Week 36 Very Severe to Severe	0			
Week 36 Very Severe to Very Severe	0			
Week 44 Mild to None (n=5, n=15, n=10, n=14, n=0)	0			
Week 44 Mild to Mild	0			
Week 44 Mild to Moderate	0			
Week 44 Mild to Severe	0			
Week 44 Mild to Very Severe	0			



Week 44 Moderate to None	0			
Week 44 Moderate to Mild	0			
Week 44 Moderate to Moderate	0			
Week 44 Moderate to Severe	0			
Week 44 Moderate to Very Severe	0			
Week 44 Severe to None	0			
Week 44 Severe to Mild	0			
Week 44 Severe to Moderate	0			
Week 44 Severe to Severe	0			
Week 44 Severe to Very Severe	0			
Week 44 Very Severe to None	0			
Week 44 Very Severe to Mild	0			
Week 44 Very Severe to Moderate	0			
Week 44 Very Severe to Severe	0			
Week 44 Very Severe to Very Severe	0			
Week 52 Mild to None (n=4, n=14, n=10, n=14, n=0)	0			
Week 52 Mild to Mild	0			
Week 52 Mild to Moderate	0			
Week 52 Mild to Severe	0			
Week 52 Mild to Very Severe	0			
Week 52 Moderate to None	0			
Week 52 Moderate to Mild	0			
Week 52 Moderate to Moderate	0			
Week 52 Moderate to Severe	0			
Week 52 Moderate to Very Severe	0			
Week 52 Severe to None	0			
Week 52 Severe to Mild	0			
Week 52 Severe to Moderate	0			
Week 52 Severe to Severe	0			
Week 52 Severe to Very Severe	0			
Week 52 Very Severe to None	0			
Week 52 Very Severe to Mild	0			
Week 52 Very Severe to Moderate	0			
Week 52 Very Severe to Severe	0			
Week 52 Very Severe to Very Severe	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Histologic Non-responders by Dose at Weeks 12, 26 and 52

End point title	Percentage of Histologic Non-responders by Dose at Weeks 12, 26 and 52
-----------------	--

End point description:

Percentage of histologic non-responders by dose at Weeks 12, 26 and 52

Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect non-response following 12 or 38 weeks of treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 12, 26 and 52

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Percentage of Participants				
number (not applicable)				
Week 12	52.4	9.1	33.3	20.0
Week 26	52.4	22.7	33.3	25.0
Week 52	76.2	27.3	47.6	40.0

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Percentage of Participants				
number (not applicable)				
Week 12	100.0			
Week 26	36.8			
Week 52	47.4			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores

End point title	Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores
-----------------	--

End point description:

Change from Baseline 7-Day Components of the Eosinophilic Esophagitis Activity Index (EEsAI): Avoidance, Modification and Slow Eating (AMS) Score, minimum 0, maximum 10; and Visual Dysphagia Question (VDQ) Score, minimum 0, maximum 10.

Higher score means a worse outcome

Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline 7-day EEsAI subscores following 12 or 38 weeks of treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 12, 26 and 52

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Mean Change from Baseline				
arithmetic mean (standard deviation)				
VDQ Week 12 (n=18, n=19, n=20, n=19, n=17)	-3.9 (± 6.63)	-2.5 (± 3.24)	-5.0 (± 6.00)	-4.1 (± 8.03)
VDQ Week 26 (n=8, n=18, n=13, n=16, n=0)	-3.1 (± 4.36)	-6.8 (± 7.03)	-6.8 (± 6.46)	-7.7 (± 9.47)
VDQ Week 52 (n=5, n=16, n=11, n=14, n=0)	-9.4 (± 9.50)	-9.4 (± 8.25)	-12.6 (± 9.67)	-9.6 (± 7.27)
AMS Week 12 (n=18, n=20, n=20, n=19, n=17)	0.0 (± 0.00)	-3.0 (± 7.80)	-1.4 (± 3.30)	-1.3 (± 6.47)
AMS Week 26 (n=8, n=19, n=13, n=15, n=0)	0.0 (± 0.00)	-2.2 (± 8.31)	-0.7 (± 4.44)	-3.3 (± 7.54)
AMS Week 52 (n=5, n=17, n=11, n=13, n=0)	0.0 (± 0.00)	-3.5 (± 8.39)	-0.8 (± 2.71)	-2.6 (± 7.17)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Mean Change from Baseline				
arithmetic mean (standard deviation)				
VDQ Week 12 (n=18, n=19, n=20, n=19, n=17)	-2.7 (± 3.41)			
VDQ Week 26 (n=8, n=18, n=13, n=16, n=0)	0 (± 0)			
VDQ Week 52 (n=5, n=16, n=11, n=14, n=0)	0 (± 0)			
AMS Week 12 (n=18, n=20, n=20, n=19, n=17)	1.5 (± 6.85)			
AMS Week 26 (n=8, n=19, n=13, n=15, n=0)	0 (± 0)			
AMS Week 52 (n=5, n=17, n=11, n=13, n=0)	0 (± 0)			

## Statistical analyses

Statistical analysis title	VDQ Score Change from Baseline Week 12
Comparison groups	APT-1011 1.5 mg HS v Placebo
Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.459
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.21

Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.49
upper limit	3.08
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	VDQ Score Change from Baseline Week 12
Comparison groups	APT-1011 1.5 mg BID v Placebo
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.617
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.58
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.65
upper limit	3.8
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	VDQ Score Change from Baseline Week 12
Comparison groups	APT-1011 3 mg HS v Placebo
Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.167
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.87
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.07
upper limit	1.33
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	VDQ Score Change from Baseline Week 12
Comparison groups	APT-1011 3 mg BID v Placebo

Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.373
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-0.63
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.88
upper limit	2.61
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	AMS Score Change from Baseline Week 12
Comparison groups	APT-1011 1.5 mg HS v Placebo
Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.203
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.66
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.96
upper limit	1.64
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	AMS Score Change from Baseline Week 12
Comparison groups	APT-1011 1.5 mg BID v Placebo
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.014
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-4.33
Confidence interval	
level	90 %
sides	2-sided
lower limit	-7.54
upper limit	-1.13
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	AMS Score Change from Baseline Week 12
Comparison groups	APT-1011 3 mg HS v Placebo
Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.061
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-3.02
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.23
upper limit	0.2
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	AMS Score Change from Baseline Week 12
Comparison groups	APT-1011 3 mg BID v Placebo
Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.097
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2.57
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.83
upper limit	0.69
Variability estimate	Standard deviation

### **Secondary: Change from Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit**

End point title	Change from Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit
End point description:	Change From Baseline PGIS for Difficulty with Food or Pills Going Down as Assessed Prior to Randomization at Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52 Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline PGIS for difficulty with food or pills going down following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment.
End point type	Secondary

End point timeframe:

Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Percentage of participants				
Week 4 Mild to None (n=20, n=19, n=20, n=19, n=15)	2	0	0	0
Week 4 Mild to Mild	1	1	1	1
Week 4 Mild to Moderate	0	0	1	1
Week 4 Mild to Severe	0	0	0	0
Week 4 Mild to Very Severe	0	0	0	0
Week 4 Moderate to None	0	0	6	0
Week 4 Moderate to Mild	6	6	4	7
Week 4 Moderate to Moderate	5	4	4	4
Week 4 Moderate to Severe	1	1	0	0
Week 4 Moderate to Very Severe	0	0	0	0
Week 4 Severe to None	0	0	1	1
Week 4 Severe to Mild	1	1	0	0
Week 4 Severe to Moderate	2	2	2	4
Week 4 Severe to Severe	1	4	0	1
Week 4 Severe to Very Severe	0	0	1	0
Week 4 Very Severe to None	0	0	0	0
Week 4 Very Severe to Mild	0	0	0	0
Week 4 Very Severe to Moderate	0	0	0	0
Week 4 Very Severe to Severe	0	0	0	0
Week 4 Very Severe to Very Severe	1	0	0	0
Week 8 Mild to None (n=17, n=21, n=19, n=19, n=16)	0	0	0	0
Week 8 Mild to Mild	2	1	2	1
Week 8 Mild to Moderate	1	0	0	1
Week 8 Mild to Severe	0	0	0	0
Week 8 Mild to Very Severe	0	0	0	0
Week 8 Moderate to None	1	1	4	2
Week 8 Moderate to Mild	8	5	5	5
Week 8 Moderate to Moderate	1	6	4	4
Week 8 Moderate to Severe	0	0	0	0
Week 8 Moderate to Very Severe	0	0	0	0
Week 8 Severe to None	1	0	1	1
Week 8 Severe to Mild	2	1	1	2
Week 8 Severe to Moderate	0	7	0	3
Week 8 Severe to Severe	0	0	1	0
Week 8 Severe to Very Severe	0	0	1	0
Week 8 Very Severe to None	0	0	0	0
Week 8 Very Severe to Mild	0	0	0	0
Week 8 Very Severe to Moderate	1	0	0	0
Week 8 Very Severe to Severe	0	0	0	0
Week 8 Very Severe to Very Severe	0	0	0	0

Week 12 Mild to None (n=18, n=20, n=20, n=18, n=17)	1	0	0	0
Week 12 Mild to Mild	2	1	2	2
Week 12 Mild to Moderate	1	0	0	0
Week 12 Mild to Severe	0	0	0	0
Week 12 Mild to Very Severe	0	0	0	0
Week 12 Moderate to None	3	0	5	3
Week 12 Moderate to Mild	4	5	6	2
Week 12 Moderate to Moderate	3	6	3	5
Week 12 Moderate to Severe	0	0	0	0
Week 12 Moderate to Very Severe	0	0	0	0
Week 12 Severe to None	3	0	1	1
Week 12 Severe to Mild	0	4	0	1
Week 12 Severe to Moderate	0	3	2	2
Week 12 Severe to Severe	0	1	1	2
Week 12 Severe to Very Severe	0	0	0	0
Week 12 Very Severe to None	0	0	0	0
Week 12 Very Severe to Mild	0	0	0	0
Week 12 Very Severe to Moderate	1	0	0	0
Week 12 Very Severe to Severe	0	0	0	0
Week 12 Very Severe to Very Severe	0	0	0	0
Week 14 Mild to None (n=10, n=18, n=13, n=15, n=0)	0	0	1	0
Week 14 Mild to Mild	1	1	0	2
Week 14 Mild to Moderate	0	0	0	0
Week 14 Mild to Severe	0	0	0	0
Week 14 Mild to Very Severe	0	0	0	0
Week 14 Moderate to None	1	0	4	3
Week 14 Moderate to Mild	7	7	3	2
Week 14 Moderate to Moderate	0	2	1	3
Week 14 Moderate to Severe	0	1	0	0
Week 14 Moderate to Very Severe	0	0	0	0
Week 14 Severe to None	0	1	0	1
Week 14 Severe to Mild	0	2	2	2
Week 14 Severe to Moderate	0	4	1	2
Week 14 Severe to Severe	0	0	1	0
Week 14 Severe to Very Severe	0	0	0	0
Week 14 Very Severe to None	0	0	0	0
Week 14 Very Severe to Mild	0	0	0	0
Week 14 Very Severe to Moderate	0	0	0	0
Week 14 Very Severe to Severe	0	0	0	0
Week 14 Very Severe to Very Severe	1	0	0	0
Week 18 Mild to None (n=9, n=18, n=14, n=14, n=0)	0	0	1	0
Week 18 Mild to Mild	0	1	0	2
Week 18 Mild to Moderate	0	0	0	0
Week 18 Mild to Severe	0	0	0	0
Week 18 Mild to Very Severe	0	0	0	0
Week 18 Moderate to None	0	1	5	4
Week 18 Moderate to Mild	8	7	3	2
Week 18 Moderate to Moderate	0	2	1	2
Week 18 Moderate to Severe	0	0	0	0
Week 18 Moderate to Very Severe	0	0	0	0



Week 18 Severe to None	0	2	1	1
Week 18 Severe to Mild	0	2	1	2
Week 18 Severe to Moderate	0	3	1	1
Week 18 Severe to Severe	0	0	1	0
Week 18 Severe to Very Severe	0	0	0	0
Week 18 Very Severe to None	0	0	0	0
Week 18 Very Severe to Mild	0	0	0	0
Week 18 Very Severe to Moderate	1	0	0	0
Week 18 Very Severe to Severe	0	0	0	0
Week 18 Very Severe to Very Severe	0	0	0	0
Week 22 Mild to None (n=8, n=18, n=13, n=16, n=0)	0	0	0	0
Week 22 Mild to Mild	0	1	1	2
Week 22 Mild to Moderate	0	0	0	0
Week 22 Mild to Severe	0	0	0	0
Week 22 Mild to Very Severe	0	0	0	0
Week 22 Moderate to None	2	1	3	4
Week 22 Moderate to Mild	6	7	3	3
Week 22 Moderate to Moderate	0	2	2	2
Week 22 Moderate to Severe	0	0	0	0
Week 22 Moderate to Very Severe	0	0	0	0
Week 22 Severe to None	0	2	1	2
Week 22 Severe to Mild	0	2	1	1
Week 22 Severe to Moderate	0	3	1	2
Week 22 Severe to Severe	0	0	0	0
Week 22 Severe to Very Severe	0	0	1	0
Week 22 Very Severe to None	0	0	0	0
Week 22 Very Severe to Mild	0	0	0	0
Week 22 Very Severe to Moderate	0	0	0	0
Week 22 Very Severe to Severe	0	0	0	0
Week 22 Very Severe to Very Severe	0	0	0	0
Week 26 Mild to None (n=8, n=17, n=13, n=16, n=0)	0	0	0	0
Week 26 Mild to Mild	0	1	1	2
Week 26 Mild to Moderate	0	0	0	0
Week 26 Mild to Severe	0	0	0	0
Week 26 Mild to Very Severe	0	0	0	0
Week 26 Moderate to None	3	0	4	5
Week 26 Moderate to Mild	3	7	3	2
Week 26 Moderate to Moderate	1	2	1	2
Week 26 Moderate to Severe	0	0	0	0
Week 26 Moderate to Very Severe	0	0	0	0
Week 26 Severe to None	0	3	2	2
Week 26 Severe to Mild	0	3	1	2
Week 26 Severe to Moderate	0	1	0	1
Week 26 Severe to Severe	0	0	1	0
Week 26 Severe to Very Severe	0	0	0	0
Week 26 Very Severe to None	0	0	0	0
Week 26 Very Severe to Mild	0	0	0	0
Week 26 Very Severe to Moderate	1	0	0	0
Week 26 Very Severe to Severe	0	0	0	0
Week 26 Very Severe to Very Severe	0	0	0	0

Week 28 Mild to None (n=7, n=16, n=10, n=14, n=0)	0	0	1	1
Week 28 Mild to Mild	0	1	0	1
Week 28 Mild to Moderate	0	0	0	0
Week 28 Mild to Severe	0	0	0	0
Week 28 Mild to Very Severe	0	0	0	0
Week 28 Moderate to None	4	0	4	4
Week 28 Moderate to Mild	2	7	1	2
Week 28 Moderate to Moderate	0	1	0	1
Week 28 Moderate to Severe	0	0	0	0
Week 28 Moderate to Very Severe	0	0	0	0
Week 28 Severe to None	0	3	2	1
Week 28 Severe to Mild	0	2	0	4
Week 28 Severe to Moderate	0	2	1	0
Week 28 Severe to Severe	0	0	1	0
Week 28 Severe to Very Severe	0	0	0	0
Week 28 Very Severe to None	0	0	0	0
Week 28 Very Severe to Mild	1	0	0	0
Week 28 Very Severe to Moderate	0	0	0	0
Week 28 Very Severe to Severe	0	0	0	0
Week 28 Very Severe to Very Severe	0	0	0	0
Week 36 Mild to None (n=6, n=15, n=11, n=14, n=0)	0	0	0	2
Week 36 Mild to Mild	0	1	1	0
Week 36 Mild to Moderate	0	0	0	0
Week 36 Mild to Severe	0	0	0	0
Week 36 Mild to Very Severe	0	0	0	0
Week 36 Moderate to None	2	2	5	4
Week 36 Moderate to Mild	3	5	1	2
Week 36 Moderate to Moderate	0	1	0	1
Week 36 Moderate to Severe	0	0	0	0
Week 36 Moderate to Very Severe	0	0	0	0
Week 36 Severe to None	0	4	2	1
Week 36 Severe to Mild	0	1	1	3
Week 36 Severe to Moderate	0	1	0	1
Week 36 Severe to Severe	0	0	0	0
Week 36 Severe to Very Severe	0	0	1	0
Week 36 Very Severe to None	0	0	0	0
Week 36 Very Severe to Mild	0	0	0	0
Week 36 Very Severe to Moderate	0	0	0	0
Week 36 Very Severe to Severe	1	0	0	0
Week 36 Very Severe to Very Severe	0	0	0	0
Week 44 Mild to None (n=5, n=15, n=10, n=14, n=0)	0	0	0	1
Week 44 Mild to Mild	0	1	1	1
Week 44 Mild to Moderate	0	0	0	0
Week 44 Mild to Severe	0	0	0	0
Week 44 Mild to Very Severe	0	0	0	0
Week 44 Moderate to None	2	1	3	4
Week 44 Moderate to Mild	2	6	1	2
Week 44 Moderate to Moderate	0	0	1	1
Week 44 Moderate to Severe	0	1	0	0
Week 44 Moderate to Very Severe	0	0	0	0

Week 44 Severe to None	0	3	2	2
Week 44 Severe to Mild	0	3	1	2
Week 44 Severe to Moderate	0	0	0	1
Week 44 Severe to Severe	0	0	0	0
Week 44 Severe to Very Severe	0	0	1	0
Week 44 Very Severe to None	0	0	0	0
Week 44 Very Severe to Mild	1	0	0	0
Week 44 Very Severe to Moderate	0	0	0	0
Week 44 Very Severe to Severe	0	0	0	0
Week 44 Very Severe to Very Severe	0	0	0	0
Week 52 Mild to None (n=4, n=14, n=10, n=14, n=0)	0	0	1	2
Week 52 Mild to Mild	0	0	0	0
Week 52 Mild to Moderate	0	1	0	0
Week 52 Mild to Severe	0	0	0	0
Week 52 Mild to Very Severe	0	0	0	0
Week 52 Moderate to None	2	2	5	6
Week 52 Moderate to Mild	2	4	1	0
Week 52 Moderate to Moderate	0	3	0	1
Week 52 Moderate to Severe	0	0	0	0
Week 52 Moderate to Very Severe	0	0	0	0
Week 52 Severe to None	0	3	1	3
Week 52 Severe to Mild	0	1	1	1
Week 52 Severe to Moderate	0	0	0	1
Week 52 Severe to Severe	0	0	0	0
Week 52 Severe to Very Severe	0	0	1	0
Week 52 Very Severe to None	0	0	0	0
Week 52 Very Severe to Mild	0	0	0	0
Week 52 Very Severe to Moderate	0	0	0	0
Week 52 Very Severe to Severe	0	0	0	0
Week 52 Very Severe to Very Severe	0	0	0	0

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Percentage of participants				
Week 4 Mild to None (n=20, n=19, n=20, n=19, n=15)	1			
Week 4 Mild to Mild	1			
Week 4 Mild to Moderate	0			
Week 4 Mild to Severe	0			
Week 4 Mild to Very Severe	0			
Week 4 Moderate to None	0			
Week 4 Moderate to Mild	5			
Week 4 Moderate to Moderate	4			
Week 4 Moderate to Severe	0			
Week 4 Moderate to Very Severe	0			
Week 4 Severe to None	0			
Week 4 Severe to Mild	0			

Week 4 Severe to Moderate	1			
Week 4 Severe to Severe	3			
Week 4 Severe to Very Severe	0			
Week 4 Very Severe to None	0			
Week 4 Very Severe to Mild	0			
Week 4 Very Severe to Moderate	0			
Week 4 Very Severe to Severe	0			
Week 4 Very Severe to Very Severe	0			
Week 8 Mild to None (n=17, n=21, n=19, n=19, n=16)	1			
Week 8 Mild to Mild	2			
Week 8 Mild to Moderate	0			
Week 8 Mild to Severe	0			
Week 8 Mild to Very Severe	0			
Week 8 Moderate to None	0			
Week 8 Moderate to Mild	6			
Week 8 Moderate to Moderate	3			
Week 8 Moderate to Severe	0			
Week 8 Moderate to Very Severe	0			
Week 8 Severe to None	0			
Week 8 Severe to Mild	1			
Week 8 Severe to Moderate	3			
Week 8 Severe to Severe	0			
Week 8 Severe to Very Severe	0			
Week 8 Very Severe to None	0			
Week 8 Very Severe to Mild	0			
Week 8 Very Severe to Moderate	0			
Week 8 Very Severe to Severe	0			
Week 8 Very Severe to Very Severe	0			
Week 12 Mild to None (n=18, n=20, n=20, n=18, n=17)	2			
Week 12 Mild to Mild	1			
Week 12 Mild to Moderate	0			
Week 12 Mild to Severe	0			
Week 12 Mild to Very Severe	0			
Week 12 Moderate to None	0			
Week 12 Moderate to Mild	6			
Week 12 Moderate to Moderate	4			
Week 12 Moderate to Severe	0			
Week 12 Moderate to Very Severe	0			
Week 12 Severe to None	0			
Week 12 Severe to Mild	1			
Week 12 Severe to Moderate	2			
Week 12 Severe to Severe	1			
Week 12 Severe to Very Severe	0			
Week 12 Very Severe to None	0			
Week 12 Very Severe to Mild	0			
Week 12 Very Severe to Moderate	0			
Week 12 Very Severe to Severe	0			
Week 12 Very Severe to Very Severe	0			
Week 14 Mild to None (n=10, n=18, n=13, n=15, n=0)	0			
Week 14 Mild to Mild	0			

Week 14 Mild to Moderate	0			
Week 14 Mild to Severe	0			
Week 14 Mild to Very Severe	0			
Week 14 Moderate to None	0			
Week 14 Moderate to Mild	0			
Week 14 Moderate to Moderate	0			
Week 14 Moderate to Severe	0			
Week 14 Moderate to Very Severe	0			
Week 14 Severe to None	0			
Week 14 Severe to Mild	0			
Week 14 Severe to Moderate	0			
Week 14 Severe to Severe	0			
Week 14 Severe to Very Severe	0			
Week 14 Very Severe to None	0			
Week 14 Very Severe to Mild	0			
Week 14 Very Severe to Moderate	0			
Week 14 Very Severe to Severe	0			
Week 14 Very Severe to Very Severe	0			
Week 18 Mild to None (n=9, n=18, n=14, n=14, n=0)	0			
Week 18 Mild to Mild	0			
Week 18 Mild to Moderate	0			
Week 18 Mild to Severe	0			
Week 18 Mild to Very Severe	0			
Week 18 Moderate to None	0			
Week 18 Moderate to Mild	0			
Week 18 Moderate to Moderate	0			
Week 18 Moderate to Severe	0			
Week 18 Moderate to Very Severe	0			
Week 18 Severe to None	0			
Week 18 Severe to Mild	0			
Week 18 Severe to Moderate	0			
Week 18 Severe to Severe	0			
Week 18 Severe to Very Severe	0			
Week 18 Very Severe to None	0			
Week 18 Very Severe to Mild	0			
Week 18 Very Severe to Moderate	0			
Week 18 Very Severe to Severe	0			
Week 18 Very Severe to Very Severe	0			
Week 22 Mild to None (n=8, n=18, n=13, n=16, n=0)	0			
Week 22 Mild to Mild	0			
Week 22 Mild to Moderate	0			
Week 22 Mild to Severe	0			
Week 22 Mild to Very Severe	0			
Week 22 Moderate to None	0			
Week 22 Moderate to Mild	0			
Week 22 Moderate to Moderate	0			
Week 22 Moderate to Severe	0			
Week 22 Moderate to Very Severe	0			
Week 22 Severe to None	0			
Week 22 Severe to Mild	0			

Week 22 Severe to Moderate	0			
Week 22 Severe to Severe	0			
Week 22 Severe to Very Severe	0			
Week 22 Very Severe to None	0			
Week 22 Very Severe to Mild	0			
Week 22 Very Severe to Moderate	0			
Week 22 Very Severe to Severe	0			
Week 22 Very Severe to Very Severe	0			
Week 26 Mild to None (n=8, n=17, n=13, n=16, n=0)	0			
Week 26 Mild to Mild	0			
Week 26 Mild to Moderate	0			
Week 26 Mild to Severe	0			
Week 26 Mild to Very Severe	0			
Week 26 Moderate to None	0			
Week 26 Moderate to Mild	0			
Week 26 Moderate to Moderate	0			
Week 26 Moderate to Severe	0			
Week 26 Moderate to Very Severe	0			
Week 26 Severe to None	0			
Week 26 Severe to Mild	0			
Week 26 Severe to Moderate	0			
Week 26 Severe to Severe	0			
Week 26 Severe to Very Severe	0			
Week 26 Very Severe to None	0			
Week 26 Very Severe to Mild	0			
Week 26 Very Severe to Moderate	0			
Week 26 Very Severe to Severe	0			
Week 26 Very Severe to Very Severe	0			
Week 28 Mild to None (n=7, n=16, n=10, n=14, n=0)	0			
Week 28 Mild to Mild	0			
Week 28 Mild to Moderate	0			
Week 28 Mild to Severe	0			
Week 28 Mild to Very Severe	0			
Week 28 Moderate to None	0			
Week 28 Moderate to Mild	0			
Week 28 Moderate to Moderate	0			
Week 28 Moderate to Severe	0			
Week 28 Moderate to Very Severe	0			
Week 28 Severe to None	0			
Week 28 Severe to Mild	0			
Week 28 Severe to Moderate	0			
Week 28 Severe to Severe	0			
Week 28 Severe to Very Severe	0			
Week 28 Very Severe to None	0			
Week 28 Very Severe to Mild	0			
Week 28 Very Severe to Moderate	0			
Week 28 Very Severe to Severe	0			
Week 28 Very Severe to Very Severe	0			
Week 36 Mild to None (n=6, n=15, n=11, n=14, n=0)	0			
Week 36 Mild to Mild	0			

Week 36 Mild to Moderate	0			
Week 36 Mild to Severe	0			
Week 36 Mild to Very Severe	0			
Week 36 Moderate to None	0			
Week 36 Moderate to Mild	0			
Week 36 Moderate to Moderate	0			
Week 36 Moderate to Severe	0			
Week 36 Moderate to Very Severe	0			
Week 36 Severe to None	0			
Week 36 Severe to Mild	0			
Week 36 Severe to Moderate	0			
Week 36 Severe to Severe	0			
Week 36 Severe to Very Severe	0			
Week 36 Very Severe to None	0			
Week 36 Very Severe to Mild	0			
Week 36 Very Severe to Moderate	0			
Week 36 Very Severe to Severe	0			
Week 36 Very Severe to Very Severe	0			
Week 44 Mild to None (n=5, n=15, n=10, n=14, n=0)	0			
Week 44 Mild to Mild	0			
Week 44 Mild to Moderate	0			
Week 44 Mild to Severe	0			
Week 44 Mild to Very Severe	0			
Week 44 Moderate to None	0			
Week 44 Moderate to Mild	0			
Week 44 Moderate to Moderate	0			
Week 44 Moderate to Severe	0			
Week 44 Moderate to Very Severe	0			
Week 44 Severe to None	0			
Week 44 Severe to Mild	0			
Week 44 Severe to Moderate	0			
Week 44 Severe to Severe	0			
Week 44 Severe to Very Severe	0			
Week 44 Very Severe to None	0			
Week 44 Very Severe to Mild	0			
Week 44 Very Severe to Moderate	0			
Week 44 Very Severe to Severe	0			
Week 44 Very Severe to Very Severe	0			
Week 52 Mild to None (n=4, n=14, n=10, n=14, n=0)	0			
Week 52 Mild to Mild	0			
Week 52 Mild to Moderate	0			
Week 52 Mild to Severe	0			
Week 52 Mild to Very Severe	0			
Week 52 Moderate to None	0			
Week 52 Moderate to Mild	0			
Week 52 Moderate to Moderate	0			
Week 52 Moderate to Severe	0			
Week 52 Moderate to Very Severe	0			
Week 52 Severe to None	0			
Week 52 Severe to Mild	0			

Week 52 Severe to Moderate	0			
Week 52 Severe to Severe	0			
Week 52 Severe to Very Severe	0			
Week 52 Very Severe to None	0			
Week 52 Very Severe to Mild	0			
Week 52 Very Severe to Moderate	0			
Week 52 Very Severe to Severe	0			
Week 52 Very Severe to Very Severe	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit

End point title	Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit
-----------------	---

End point description:

Change From Baseline PGIC for EoE Symptoms as Assessed Prior to Randomization at Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52

Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline PGIC for EoE symptoms following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 4, 8, 12, 14, 18, 22, 26, 36, 44, and 52

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Percentage of participants				
Week 4 Much Worse (n=21, n=20, n=20, n=20, n=16)	0	0	0	0
Week 4 Moderately Worse	0	0	0	0
Week 4 A Little Worse	1	0	1	2
Week 4 Stayed the Same	4	4	4	3
Week 4 A Little Improved	9	9	4	10
Week 4 Moderately Improved	4	3	6	2
Week 4 Much Improved	3	4	5	3
Week 8 Much Worse (n=17, n=22, n=19, n=20, n=16)	0	0	0	0
Week 8 Moderately Worse	0	0	0	0
Week 8 A Little Worse	1	0	1	0
Week 8 Stayed the Same	2	3	3	3
Week 8 A Little Improved	4	9	5	7
Week 8 Moderately Improved	7	4	4	6
Week 8 Much Improved	3	6	6	4



Week 12 Much Worse (n=18, n=22, n=20, n=19, n=17)	0	0	0	0
Week 12 Moderately Worse	0	0	0	1
Week 12 A Little Worse	0	0	1	1
Week 12 Stayed the Same	1	4	4	3
Week 12 A Little Improved	6	5	2	6
Week 12 Moderately Improved	5	5	4	3
Week 12 Much Improved	6	8	9	5
Week 14 Much Worse (n=10, n=18, n=13, n=15, n=0)	0	0	0	0
Week 14 Moderately Worse	0	0	0	0
Week 14 A Little Worse	0	0	1	1
Week 14 Stayed the Same	0	3	1	1
Week 14 A Little Improved	3	4	1	5
Week 14 Moderately Improved	5	3	3	3
Week 14 Much Improved	2	8	7	5
Week 18 Much Worse (n=9, n=18, n=14, n=14, n=0)	0	0	0	0
Week 18 Moderately Worse	0	0	1	0
Week 18 A Little Worse	0	1	1	0
Week 18 Stayed the Same	0	3	0	1
Week 18 A Little Improved	2	1	1	4
Week 18 Moderately Improved	6	2	1	3
Week 18 Much Improved	1	11	10	6
Week 22 Much Worse (n=8, n=18, n=14, n=16, n=0)	0	0	1	0
Week 22 Moderately Worse	0	0	1	0
Week 22 A Little Worse	0	0	0	1
Week 22 Stayed the Same	0	3	0	1
Week 22 A Little Improved	2	1	2	5
Week 22 Moderately Improved	2	3	3	1
Week 22 Much Improved	4	11	7	8
Week 26 Much Worse (n=8, n=18, n=13, n=16, n=0)	0	0	0	0
Week 26 Moderately Worse	0	0	2	1
Week 26 A Little Worse	0	0	0	0
Week 26 Stayed the Same	0	2	0	1
Week 26 A Little Improved	3	1	0	4
Week 26 Moderately Improved	1	2	2	0
Week 26 Much Improved	4	13	9	10
Week 28 Much Worse (n=7, n=17, n=10, n=14, n=0)	0	0	0	0
Week 28 Moderately Worse	0	0	1	0
Week 28 A Little Worse	0	0	0	0
Week 28 Stayed the Same	0	3	0	0
Week 28 A Little Improved	1	0	1	2
Week 28 Moderately Improved	2	3	0	2
Week 28 Much Improved	4	11	8	10
Week 36 Much Worse (n=6, n=16, n=11, n=14, n=0)	0	0	0	0
Week 36 Moderately Worse	0	0	0	0
Week 36 A Little Worse	0	0	0	0
Week 36 Stayed the Same	1	0	1	0
Week 36 A Little Improved	1	1	0	3

Week 36 Moderately Improved	1	1	0	2
Week 36 Much Improved	3	14	10	9
Week 44 Much Worse (n=5, n=15, n=11, n=14, n=0)	0	0	1	0
Week 44 Moderately Worse	0	0	0	0
Week 44 A Little Worse	0	0	0	0
Week 44 Stayed the Same	0	0	0	0
Week 44 A Little Improved	1	2	0	2
Week 44 Moderately Improved	1	1	2	2
Week 44 Much Improved	3	12	8	10
Week 52 Much Worse (n=4, n=14, n=10, n=14, n=0)	0	0	0	0
Week 52 Moderately Worse	0	0	0	0
Week 52 A Little Worse	0	0	1	0
Week 52 Stayed the Same	0	1	0	0
Week 52 A Little Improved	1	0	0	2
Week 52 Moderately Improved	2	3	1	1
Week 52 Much Improved	1	10	8	11

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Percentage of participants				
Week 4 Much Worse (n=21, n=20, n=20, n=20, n=16)	0			
Week 4 Moderately Worse	1			
Week 4 A Little Worse	0			
Week 4 Stayed the Same	6			
Week 4 A Little Improved	4			
Week 4 Moderately Improved	4			
Week 4 Much Improved	1			
Week 8 Much Worse (n=17, n=22, n=19, n=20, n=16)	0			
Week 8 Moderately Worse	0			
Week 8 A Little Worse	0			
Week 8 Stayed the Same	3			
Week 8 A Little Improved	6			
Week 8 Moderately Improved	5			
Week 8 Much Improved	2			
Week 12 Much Worse (n=18, n=22, n=20, n=19, n=17)	0			
Week 12 Moderately Worse	0			
Week 12 A Little Worse	1			
Week 12 Stayed the Same	4			
Week 12 A Little Improved	2			
Week 12 Moderately Improved	8			
Week 12 Much Improved	2			
Week 14 Much Worse (n=10, n=18, n=13, n=15, n=0)	0			
Week 14 Moderately Worse	0			
Week 14 A Little Worse	0			

Week 14 Stayed the Same	0			
Week 14 A Little Improved	0			
Week 14 Moderately Improved	0			
Week 14 Much Improved	0			
Week 18 Much Worse (n=9, n=18, n=14, n=14, n=0)	0			
Week 18 Moderately Worse	0			
Week 18 A Little Worse	0			
Week 18 Stayed the Same	0			
Week 18 A Little Improved	0			
Week 18 Moderately Improved	0			
Week 18 Much Improved	0			
Week 22 Much Worse (n=8, n=18, n=14, n=16, n=0)	0			
Week 22 Moderately Worse	0			
Week 22 A Little Worse	0			
Week 22 Stayed the Same	0			
Week 22 A Little Improved	0			
Week 22 Moderately Improved	0			
Week 22 Much Improved	0			
Week 26 Much Worse (n=8, n=18, n=13, n=16, n=0)	0			
Week 26 Moderately Worse	0			
Week 26 A Little Worse	0			
Week 26 Stayed the Same	0			
Week 26 A Little Improved	0			
Week 26 Moderately Improved	0			
Week 26 Much Improved	0			
Week 28 Much Worse (n=7, n=17, n=10, n=14, n=0)	0			
Week 28 Moderately Worse	0			
Week 28 A Little Worse	0			
Week 28 Stayed the Same	0			
Week 28 A Little Improved	0			
Week 28 Moderately Improved	0			
Week 28 Much Improved	0			
Week 36 Much Worse (n=6, n=16, n=11, n=14, n=0)	0			
Week 36 Moderately Worse	0			
Week 36 A Little Worse	0			
Week 36 Stayed the Same	0			
Week 36 A Little Improved	0			
Week 36 Moderately Improved	0			
Week 36 Much Improved	0			
Week 44 Much Worse (n=5, n=15, n=11, n=14, n=0)	0			
Week 44 Moderately Worse	0			
Week 44 A Little Worse	0			
Week 44 Stayed the Same	0			
Week 44 A Little Improved	0			
Week 44 Moderately Improved	0			
Week 44 Much Improved	0			
Week 52 Much Worse (n=4, n=14, n=10, n=14, n=0)	0			

Week 52 Moderately Worse	0			
Week 52 A Little Worse	0			
Week 52 Stayed the Same	0			
Week 52 A Little Improved	0			
Week 52 Moderately Improved	0			
Week 52 Much Improved	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline PGIC of Difficulty with Food or Pills as Assessed Prior to Randomization Post-Baseline Visit

End point title	Change From Baseline PGIC of Difficulty with Food or Pills as Assessed Prior to Randomization Post-Baseline Visit
-----------------	---

End point description:

Change From Baseline PGIC of Difficulty with Food or Pills as Assessed Prior to Randomization at Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52

Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline PGIC of difficulty with food or pills following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 4, 8, 12, 14, 18, 22, 26, 36, 44, and 52

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Percentage of participants				
Week 4 Much Worse (n=21, n=20, n=20, n=20, n=16)	0	0	0	0
Week 4 Moderately Worse	0	0	0	0
Week 4 A Little Worse	1	0	2	1
Week 4 Stayed the Same	4	3	4	5
Week 4 A Little Improved	8	10	4	9
Week 4 Moderately Improved	6	5	4	2
Week 4 Much Improved	2	2	6	3
Week 8 Much Worse (n=17, n=22, n=19, n=20, n=16)	0	0	1	0
Week 8 Moderately Worse	0	0	0	0
Week 8 A Little Worse	2	0	1	0
Week 8 Stayed the Same	2	5	1	4
Week 8 A Little Improved	3	5	5	5
Week 8 Moderately Improved	6	4	3	7
Week 8 Much Improved	4	8	8	4
Week 12 Much Worse (n=18, n=22, n=20, n=19, n=17)	0	0	0	0
Week 12 Moderately Worse	0	0	0	1

Week 12 A Little Worse	0	0	2	1
Week 12 Stayed the Same	1	4	2	3
Week 12 A Little Improved	5	5	5	5
Week 12 Moderately Improved	6	4	2	3
Week 12 Much Improved	6	9	9	6
Week 14 Much Worse (n=10, n=18, n=13, n=15, n=0)	0	0	0	0
Week 14 Moderately Worse	0	0	0	0
Week 14 A Little Worse	0	0	2	0
Week 14 Stayed the Same	0	4	0	3
Week 14 A Little Improved	3	3	1	4
Week 14 Moderately Improved	4	3	2	3
Week 14 Much Improved	3	8	8	5
Week 18 Much Worse (n=9, n=18, n=14, n=14, n=0)	0	0	0	0
Week 18 Moderately Worse	0	0	1	0
Week 18 A Little Worse	0	1	1	1
Week 18 Stayed the Same	0	3	0	0
Week 18 A Little Improved	1	1	1	2
Week 18 Moderately Improved	6	4	2	4
Week 18 Much Improved	2	9	9	7
Week 22 Much Worse (n=8, n=18, n=14, n=16, n=0)	0	0	1	0
Week 22 Moderately Worse	0	0	1	0
Week 22 A Little Worse	0	0	0	1
Week 22 Stayed the Same	0	2	0	1
Week 22 A Little Improved	2	2	2	5
Week 22 Moderately Improved	2	5	3	0
Week 22 Much Improved	4	9	7	9
Week 26 Much Worse (n=8, n=18, n=13, n=16, n=0)	0	0	0	0
Week 26 Moderately Worse	0	0	2	1
Week 26 A Little Worse	0	1	0	0
Week 26 Stayed the Same	0	2	0	1
Week 26 A Little Improved	2	0	0	3
Week 26 Moderately Improved	4	3	2	1
Week 26 Much Improved	2	12	9	10
Week 28 Much Worse (n=7, n=17, n=10, n=14, n=0)	0	0	0	0
Week 28 Moderately Worse	0	0	1	0
Week 28 A Little Worse	0	0	0	0
Week 28 Stayed the Same	0	2	0	0
Week 28 A Little Improved	1	1	1	1
Week 28 Moderately Improved	2	3	0	4
Week 28 Much Improved	4	11	8	9
Week 36 Much Worse (n=6, n=16, n=11, n=14, n=0)	0	0	0	0
Week 36 Moderately Worse	0	0	0	0
Week 36 A Little Worse	0	0	0	0
Week 36 Stayed the Same	0	1	1	0
Week 36 A Little Improved	1	0	0	2
Week 36 Moderately Improved	3	3	0	3
Week 36 Much Improved	2	12	10	9

Week 44 Much Worse (n=5, n=15, n=11, n=14, n=0)	0	0	1	0
Week 44 Moderately Worse	0	0	0	0
Week 44 A Little Worse	0	0	0	0
Week 44 Stayed the Same	0	1	0	0
Week 44 A Little Improved	1	0	0	2
Week 44 Moderately Improved	1	1	2	2
Week 44 Much Improved	3	13	8	10
Week 52 Much Worse (n=4, n=14, n=10, n=14, n=0)	0	0	0	0
Week 52 Moderately Worse	0	0	0	0
Week 52 A Little Worse	0	1	1	0
Week 52 Stayed the Same	1	0	0	0
Week 52 A Little Improved	0	0	0	2
Week 52 Moderately Improved	1	5	1	3
Week 52 Much Improved	2	8	8	9

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Percentage of participants				
Week 4 Much Worse (n=21, n=20, n=20, n=20, n=16)	0			
Week 4 Moderately Worse	0			
Week 4 A Little Worse	1			
Week 4 Stayed the Same	5			
Week 4 A Little Improved	7			
Week 4 Moderately Improved	2			
Week 4 Much Improved	1			
Week 8 Much Worse (n=17, n=22, n=19, n=20, n=16)	0			
Week 8 Moderately Worse	0			
Week 8 A Little Worse	1			
Week 8 Stayed the Same	4			
Week 8 A Little Improved	5			
Week 8 Moderately Improved	5			
Week 8 Much Improved	1			
Week 12 Much Worse (n=18, n=22, n=20, n=19, n=17)	0			
Week 12 Moderately Worse	0			
Week 12 A Little Worse	0			
Week 12 Stayed the Same	3			
Week 12 A Little Improved	6			
Week 12 Moderately Improved	6			
Week 12 Much Improved	2			
Week 14 Much Worse (n=10, n=18, n=13, n=15, n=0)	0			
Week 14 Moderately Worse	0			
Week 14 A Little Worse	0			
Week 14 Stayed the Same	0			
Week 14 A Little Improved	0			

Week 14 Moderately Improved	0			
Week 14 Much Improved	0			
Week 18 Much Worse (n=9, n=18, n=14, n=14, n=0)	0			
Week 18 Moderately Worse	0			
Week 18 A Little Worse	0			
Week 18 Stayed the Same	0			
Week 18 A Little Improved	0			
Week 18 Moderately Improved	0			
Week 18 Much Improved	0			
Week 22 Much Worse (n=8, n=18, n=14, n=16, n=0)	0			
Week 22 Moderately Worse	0			
Week 22 A Little Worse	0			
Week 22 Stayed the Same	0			
Week 22 A Little Improved	0			
Week 22 Moderately Improved	0			
Week 22 Much Improved	0			
Week 26 Much Worse (n=8, n=18, n=13, n=16, n=0)	0			
Week 26 Moderately Worse	0			
Week 26 A Little Worse	0			
Week 26 Stayed the Same	0			
Week 26 A Little Improved	0			
Week 26 Moderately Improved	0			
Week 26 Much Improved	0			
Week 28 Much Worse (n=7, n=17, n=10, n=14, n=0)	0			
Week 28 Moderately Worse	0			
Week 28 A Little Worse	0			
Week 28 Stayed the Same	0			
Week 28 A Little Improved	0			
Week 28 Moderately Improved	0			
Week 28 Much Improved	0			
Week 36 Much Worse (n=6, n=16, n=11, n=14, n=0)	0			
Week 36 Moderately Worse	0			
Week 36 A Little Worse	0			
Week 36 Stayed the Same	0			
Week 36 A Little Improved	0			
Week 36 Moderately Improved	0			
Week 36 Much Improved	0			
Week 44 Much Worse (n=5, n=15, n=11, n=14, n=0)	0			
Week 44 Moderately Worse	0			
Week 44 A Little Worse	0			
Week 44 Stayed the Same	0			
Week 44 A Little Improved	0			
Week 44 Moderately Improved	0			
Week 44 Much Improved	0			
Week 52 Much Worse (n=4, n=14, n=10, n=14, n=0)	0			
Week 52 Moderately Worse	0			
Week 52 A Little Worse	0			

Week 52 Stayed the Same	0			
Week 52 A Little Improved	0			
Week 52 Moderately Improved	0			
Week 52 Much Improved	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of subjects requiring emergency endoscopic food dis-impaction

End point title	Percentage of subjects requiring emergency endoscopic food dis-impaction
-----------------	--

End point description:

Percentage of subjects requiring emergency endoscopic food dis-impaction by dose before Week 14, between Week 14 and Week 28, and between Week 28 and Week 52

Note: There were no patients in the placebo group after Week 14.

End point type	Secondary
----------------	-----------

End point timeframe:

before Week 14, between Week 14 and Week 28, between Week 28 and Week 52

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Percentage of participants				
Before Week 14	0	0	0	0
Between Week 14 and Week 28	0	0	0	0
Between Week 28 and Week 52	0	0	0	0

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Percentage of participants				
Before Week 14	0			
Between Week 14 and Week 28	0			
Between Week 28 and Week 52	0			

## Statistical analyses

No statistical analyses for this end point



---

**Secondary: Percentage of subjects requiring esophageal dilation**

---

End point title	Percentage of subjects requiring esophageal dilation
-----------------	--

End point description:

Percentage of subjects requiring esophageal dilation by dosing group and part of the study

Note: There were no patients in the placebo group after Week 14.

End point type	Secondary
----------------	-----------

End point timeframe:

baseline to Week 52

---

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Percentage of participants	0	0	0	0

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Percentage of participants	0			

---

**Statistical analyses**

---

No statistical analyses for this end point

---

---

**Other pre-specified: Number of Subjects Discontinuing Due to HPA Axis Suppression**

---

End point title	Number of Subjects Discontinuing Due to HPA Axis Suppression
-----------------	--

End point description:

Number of subjects discontinuing due to HPA axis suppression in the Safety Analysis Population

Note: There were no patients in the placebo group after Week 14.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

baseline to Week 52

---

End point values	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Count of Participants	0	0	0	0

<b>End point values</b>	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Count of Participants	0			

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Frequency of Oral and Esophageal Candidiasis

End point title	Frequency of Oral and Esophageal Candidiasis
End point description:	
Frequency of oral and esophageal candidiasis in the Safety Analysis Population	
Note: There were no patients in the placebo group after Week 14.	
End point type	Other pre-specified
End point timeframe:	
baseline to Week 52	

<b>End point values</b>	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS	APT-1011 3 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	22	21	20
Units: Count of Participants				
Oesophageal candidiasis	0	2	0	8
Oral candidiasis	0	3	1	3

<b>End point values</b>	Placebo	Single-Blind APT-1011 3 mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	34		
Units: Count of Participants				
Oesophageal candidiasis	0	1		
Oral candidiasis	0	1		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events were reported from the time of enrollment until the completion of the Follow-Up Visit which took place 2 weeks after the subject took the final dose of the study drug, if applicable.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

### Reporting groups

Reporting group title	APT-1011 1.5 mg HS
-----------------------	--------------------

Reporting group description:

Subjects received placebo 30 minutes after breakfast and 1.5 mg APT-1011 HS (at bedtime) daily

Reporting group title	APT-1011 1.5 mg BID
-----------------------	---------------------

Reporting group description:

Subjects received 1.5 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 3.0 mg

Reporting group title	APT-1011 3 mg HS
-----------------------	------------------

Reporting group description:

Subjects received placebo 30 minutes after breakfast and 3.0 mg APT-1011 at bedtime daily

Reporting group title	APT-1011 3 mg BID
-----------------------	-------------------

Reporting group description:

Subjects received 3 mg APT-1011 30 minutes after breakfast and at bedtime daily for a total daily dose of 6.0 mg

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received placebo 30 minutes after breakfast and HS (at bedtime) daily

Reporting group title	Single-Blind APT-1011 3 mg BID
-----------------------	--------------------------------

Reporting group description: -

Serious adverse events	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	2 / 21 (9.52%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hodgkin's disease			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Status epilepticus			

subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Ureterolithiasis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	APT-1011 3 mg BID	Placebo	Single-Blind APT-1011 3 mg BID
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hodgkin's disease			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Status epilepticus			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Ureterolithiasis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	APT-1011 1.5 mg HS	APT-1011 1.5 mg BID	APT-1011 3 mg HS
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 21 (47.62%)	20 / 23 (86.96%)	16 / 21 (76.19%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cartilage neoplasm			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 21 (0.00%)	2 / 23 (8.70%)	1 / 21 (4.76%)
occurrences (all)	0	4	1
General disorders and administration site conditions			
Chills			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Early satiety			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Gait disturbance			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Generalised oedema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0

Oedema peripheral subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Peripheral swelling subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	1 / 21 (4.76%) 1
Pyrexia subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Temperature regulation disorder subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Reproductive system and breast disorders Benign prostatic hyperplasia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Epididymal cyst subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Genital rash subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Gynaecomastia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	1 / 21 (4.76%) 1
Menstruation irregular			

subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Pelvic discomfort			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Peyronie's disease			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Prostatitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Asthma			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Dyspnoea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Hyperventilation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Laryngeal inflammation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	2 / 21 (9.52%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	3	1	0
Oropharyngeal pain			

subjects affected / exposed	2 / 21 (9.52%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	2	0	0
Oropharyngeal spasm			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Pulmonary congestion			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Sinus congestion			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Tonsillolith			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Depressed mood			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Insomnia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Libido decreased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Post-traumatic stress disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Stress			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0



Investigations			
ACTH stimulation test abnormal			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Alanine aminotransferase increased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	1	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	1	0	1
Blood bilirubin increased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Blood glucose increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Blood pressure increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Cortisol decreased			
subjects affected / exposed	1 / 21 (4.76%)	2 / 23 (8.70%)	1 / 21 (4.76%)
occurrences (all)	1	2	1
Electrocardiogram QRS complex prolonged			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Heart rate increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count increased			

subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Neutrophil percentage decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Protein urine present			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Weight increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Arthropod bite			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Back injury			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Concussion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Corneal abrasion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Eye injury			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Hand fracture			

subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Muscle rupture			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Muscle strain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Road traffic accident			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	2 / 21 (9.52%)
occurrences (all)	0	0	2
Tooth fracture			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Wound			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Gilbert's syndrome			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Atrioventricular block first degree			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Bundle branch block right			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Palpitations			

subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	1 / 21 (4.76%) 1
Nervous system disorders			
Carpal tunnel syndrome			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Cervical radiculopathy			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Dizziness			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 21 (4.76%)	2 / 23 (8.70%)	2 / 21 (9.52%)
occurrences (all)	7	2	2
Migraine			
subjects affected / exposed	1 / 21 (4.76%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	1	1	0
Somnolence			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Syncope			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Taste disorder			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			

Deafness bilateral subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 23 (4.35%) 1	0 / 21 (0.00%) 0
Ear pain subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Middle ear effusion subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 23 (4.35%) 1	0 / 21 (0.00%) 0
Abdominal distension subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	1 / 21 (4.76%) 1
Abdominal pain lower subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	1 / 21 (4.76%) 1
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Angular cheilitis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 23 (0.00%) 0	2 / 21 (9.52%) 2
Diarrhoea haemorrhagic			

subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	1 / 21 (4.76%)	2 / 23 (8.70%)	2 / 21 (9.52%)
occurrences (all)	1	2	2
Dysphagia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Erosive oesophagitis			
subjects affected / exposed	1 / 21 (4.76%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	1	1	0
Faeces pale			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Faeces soft			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	1 / 21 (4.76%)	2 / 23 (8.70%)	0 / 21 (0.00%)
occurrences (all)	1	2	0
Gastric mucosa erythema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Gastric polyps			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Gastritis erosive			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Gastritis haemorrhagic			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 21 (4.76%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	1	1	0
Glossodynia			

subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Haemorrhoids thrombosed			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Hiatus hernia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 21 (0.00%)	2 / 23 (8.70%)	1 / 21 (4.76%)
occurrences (all)	0	2	1
Odynophagia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Oesophageal food impaction			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Oesophageal ulcer			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Oesophagitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	2 / 21 (9.52%)
occurrences (all)	0	0	2
Oral pain			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Paraesthesia oral			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Stomatitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Vomiting			

subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	1 / 23 (4.35%) 1	1 / 21 (4.76%) 1
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Cutaneous calcification			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Ingrowing nail			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Pityriasis rosea			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Pruritus allergic			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Rash vesicular			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Rosacea			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			



Hypertonic bladder subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	1 / 21 (4.76%) 1
Nephrolithiasis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Proteinuria subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Endocrine disorders Adrenal suppression subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	1 / 21 (4.76%) 1
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	1 / 23 (4.35%) 1	0 / 21 (0.00%) 0
Arthritis subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	2 / 23 (8.70%) 2	0 / 21 (0.00%) 0
Flank pain subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Joint effusion subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Joint swelling subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 23 (4.35%) 1	0 / 21 (0.00%) 0
Muscle spasms			

subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	1 / 21 (4.76%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	2	1	0
Neck pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Rotator cuff syndrome			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Tendonitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Tenosynovitis stenosaurs			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Bacterial vaginosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Bronchitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Cellulitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0

Conjunctivitis viral			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Epididymitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Fungal infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	1 / 21 (4.76%)	2 / 23 (8.70%)	1 / 21 (4.76%)
occurrences (all)	1	2	1
Gastroenteritis viral			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Genital infection fungal			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Helicobacter infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Impetigo			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Infectious mononucleosis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	0 / 21 (0.00%)	2 / 23 (8.70%)	1 / 21 (4.76%)
occurrences (all)	0	2	1
Kidney infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1

Nasopharyngitis			
subjects affected / exposed	3 / 21 (14.29%)	4 / 23 (17.39%)	1 / 21 (4.76%)
occurrences (all)	7	4	1
Oral candidiasis			
subjects affected / exposed	0 / 21 (0.00%)	3 / 23 (13.04%)	1 / 21 (4.76%)
occurrences (all)	0	3	1
Oral infection			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal candidiasis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Oesophageal candidiasis			
subjects affected / exposed	0 / 21 (0.00%)	2 / 23 (8.70%)	0 / 21 (0.00%)
occurrences (all)	0	4	0
Otitis media			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Pharyngitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	1 / 23 (4.35%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Sinusitis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 23 (0.00%)	1 / 21 (4.76%)
occurrences (all)	1	0	1
Tinea infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 21 (0.00%)	0 / 23 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	2 / 23 (8.70%)	3 / 21 (14.29%)
occurrences (all)	0	3	3

Urinary tract infection subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	2 / 23 (8.70%) 2	1 / 21 (4.76%) 1
Viral infection subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 23 (0.00%) 0	2 / 21 (9.52%) 2
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Gastrointestinal viral infection subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Metabolism and nutrition disorders			
Appetite disorder subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Dehydration subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Glucose tolerance impaired subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0
Hypercholesterolaemia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	1 / 21 (4.76%) 1
Hypovitaminosis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 23 (0.00%) 0	1 / 21 (4.76%) 1
Type 2 diabetes mellitus subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 23 (0.00%) 0	0 / 21 (0.00%) 0

<b>Non-serious adverse events</b>	APT-1011 3 mg BID	Placebo	Single-Blind APT-1011 3 mg BID
-----------------------------------	-------------------	---------	--------------------------------

Total subjects affected by non-serious adverse events			
subjects affected / exposed	19 / 20 (95.00%)	6 / 19 (31.58%)	21 / 34 (61.76%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cartilage neoplasm			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chills			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Early satiety			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Face oedema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	1 / 20 (5.00%)	3 / 19 (15.79%)	0 / 34 (0.00%)
occurrences (all)	1	3	0
Gait disturbance			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Generalised oedema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Influenza like illness			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Non-cardiac chest pain			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Oedema peripheral			

subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Peripheral swelling			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Temperature regulation disorder			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Epididymal cyst			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Erectile dysfunction			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Genital rash			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Gynaecomastia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Menstruation irregular			

subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Pelvic discomfort			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Peyronie's disease			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Prostatitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Asthma			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Cough			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Dyspnoea			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Hyperventilation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Laryngeal inflammation			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Nasal congestion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			



subjects affected / exposed	2 / 20 (10.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	2	0	0
Oropharyngeal spasm			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Pulmonary congestion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Sinus congestion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Tonsillolith			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	2 / 20 (10.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	2	0	0
Depressed mood			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Depression			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Libido decreased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Post-traumatic stress disorder			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Stress			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1

Investigations			
ACTH stimulation test abnormal			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Blood bilirubin increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Blood glucose increased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Blood pressure increased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Cortisol decreased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	2 / 34 (5.88%)
occurrences (all)	1	0	2
Electrocardiogram QRS complex prolonged			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Heart rate increased			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Lymphocyte count increased			

subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Neutrophil count decreased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Neutrophil percentage decreased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Protein urine present			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Weight increased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			
Arthropod bite			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Back injury			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Concussion			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Contusion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Corneal abrasion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Eye injury			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Hand fracture			

subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Limb injury			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Muscle rupture			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Road traffic accident			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Skin laceration			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Tooth fracture			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Congenital, familial and genetic disorders			
Gilbert's syndrome			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrioventricular block first degree			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Bundle branch block right			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Palpitations			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 19 (0.00%) 0	0 / 34 (0.00%) 0
Nervous system disorders			
Carpal tunnel syndrome			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Cervical radiculopathy			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Headache			
subjects affected / exposed	3 / 20 (15.00%)	2 / 19 (10.53%)	2 / 34 (5.88%)
occurrences (all)	4	2	3
Migraine			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Neutropenia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Ear and labyrinth disorders			

Deafness bilateral			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Middle ear effusion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Abdominal pain lower			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Angular cheilitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	2 / 20 (10.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	3	1	0
Diarrhoea haemorrhagic			

subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	1 / 20 (5.00%)	1 / 19 (5.26%)	2 / 34 (5.88%)
occurrences (all)	1	1	2
Dysphagia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Erosive oesophagitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Faeces pale			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Faeces soft			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Gastric mucosa erythema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Gastric polyps			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Gastritis erosive			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Gastritis haemorrhagic			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Glossodynia			

subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids thrombosed			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Hiatus hernia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Nausea			
subjects affected / exposed	1 / 20 (5.00%)	1 / 19 (5.26%)	1 / 34 (2.94%)
occurrences (all)	1	1	1
Odynophagia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Oesophageal food impaction			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Oesophageal ulcer			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Oesophagitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Oral pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Paraesthesia oral			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Toothache			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	2 / 34 (5.88%)
occurrences (all)	0	0	2
Vomiting			



subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 19 (0.00%) 0	0 / 34 (0.00%) 0
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Cutaneous calcification			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Dermatitis contact			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Ingrowing nail			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Pityriasis rosea			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Pruritus allergic			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Rash			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Rash vesicular			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Rosacea			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			

Hypertonic bladder subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 19 (0.00%) 0	0 / 34 (0.00%) 0
Nephrolithiasis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 19 (0.00%) 0	1 / 34 (2.94%) 1
Proteinuria subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 19 (5.26%) 1	0 / 34 (0.00%) 0
Endocrine disorders			
Adrenal suppression subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 19 (0.00%) 0	0 / 34 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 19 (0.00%) 0	0 / 34 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 19 (0.00%) 0	0 / 34 (0.00%) 0
Arthritis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 19 (0.00%) 0	0 / 34 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	3 / 20 (15.00%) 3	0 / 19 (0.00%) 0	1 / 34 (2.94%) 1
Flank pain subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 19 (0.00%) 0	0 / 34 (0.00%) 0
Joint effusion subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 19 (0.00%) 0	0 / 34 (0.00%) 0
Joint swelling subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 19 (0.00%) 0	0 / 34 (0.00%) 0
Muscle spasms			

subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Musculoskeletal chest pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	2 / 20 (10.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	2	0	0
Rotator cuff syndrome			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Tendonitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Tenosynovitis stenosaurs			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Bacterial vaginosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0

Conjunctivitis viral			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Ear infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Epididymitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Fungal infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Gastroenteritis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Genital infection fungal			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Helicobacter infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Impetigo			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Infectious mononucleosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Kidney infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0

Nasopharyngitis			
subjects affected / exposed	5 / 20 (25.00%)	1 / 19 (5.26%)	4 / 34 (11.76%)
occurrences (all)	5	1	4
Oral candidiasis			
subjects affected / exposed	3 / 20 (15.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	3	0	1
Oral infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal candidiasis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Oesophageal candidiasis			
subjects affected / exposed	8 / 20 (40.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	8	0	1
Otitis media			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	2 / 20 (10.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	2	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Tinea infection			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Tooth abscess			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 20 (10.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	2	0	0

Urinary tract infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Viral infection			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Vulvovaginal mycotic infection			
subjects affected / exposed	2 / 20 (10.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	2	0	0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Appetite disorder			
subjects affected / exposed	0 / 20 (0.00%)	1 / 19 (5.26%)	0 / 34 (0.00%)
occurrences (all)	0	1	0
Dehydration			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Glucose tolerance impaired			
subjects affected / exposed	1 / 20 (5.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Hypovitaminosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 20 (0.00%)	0 / 19 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 May 2017	<ul style="list-style-type: none"> <li>• To update secondary endpoints and statistical analyses after United States (US) Food and Drug Administration (FDA)'s review of the protocol;</li> <li>• To clarify further the history of strictures and prior steroid responses;</li> <li>• To clarify that EoE Symptom Score was to remain &gt;3 at all visits before randomization;</li> <li>• To confirm that diet was to remain stable after signing the Informed Consent Form (ICF);</li> <li>• To move the change in number of dysphagia episodes at baseline from exploratory to a secondary endpoint;</li> <li>• To clarify the schedule of visits at which adrenocorticotrophic hormone (ACTH) is assessed;</li> <li>• To add oral and esophageal candidiasis to safety endpoints;</li> <li>• To update statistical methodology to include the Cochran-Mantel-Hanzel common odds ratio test and update analysis of secondary and exploratory efficacy;</li> <li>• To include additional variables to the population pharmacokinetics (PopPK) model;</li> <li>• To clarify time points in the study for assignment to single-blind treatment;</li> <li>• To update the address of the central electrocardiogram (ECG) facility;</li> <li>• Address inconsistencies between synopsis, protocol and schedules of assessment;</li> </ul>
06 September 2017	<ul style="list-style-type: none"> <li>• To address items raised by regulatory authorities in Canada, Belgium and Germany to provide additional clarity to the protocol.</li> <li>• To update an exclusion criterion with the correct level of serum cortisol and clarify that cosyntropin will be administered intramuscularly as well as the timing of the first ACTH stimulation test;</li> <li>• To clarify the timing of the analysis of the primary endpoint and safety analyses;</li> <li>• To update the definition of high-dose proton pump inhibitors (PPI);</li> <li>• To clarify location of text for signs and symptoms of adrenal suppression and hypercorticism;</li> <li>• To clarify the definition of dysphagia;</li> <li>• To amend exclusion criteria to exclude subjects with uncontrolled diabetes or hypertension;</li> <li>• To clarify that subjects with morning serum cortisol levels (<math>\leq 5 \mu\text{g/dL}</math> [<math>138 \text{ nmol/L}</math>]) not responsive to ACTH stimulation are to be excluded;</li> <li>• To add leukotrienes and cromolyn sodium to exclusion criteria;</li> <li>• To clarify testing required for infections with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) as part of exclusion criteria;</li> <li>• To exclude subjects with documented active peptic ulcer;</li> <li>• To exclude subjects with chronic infections such as tuberculosis (TB), active chicken pox or measles or absence of measles, mumps and rubella vaccine (MMR), other malignancies and severe bleeding disorders;</li> <li>• To provide guidance of allowed amount of alcohol use;</li> <li>• To clarify previous participation in clinical trials;</li> <li>• To clarify that the ACTH stimulation test does not have to be following receipt of the morning serum cortisol level;</li> <li>• To include Switzerland to the list of countries;</li> <li>• To include optional HbA1C testing;</li> <li>• To update Schedules of Events as applicable;</li> <li>• To move the change in number of dysphagia episodes at baseline from exploratory to a secondary endpoint in the study schematic;</li> <li>• To clarify acceptable contraception for female and male subjects;</li> </ul>

16 July 2019	<ul style="list-style-type: none"> <li>o To clarify the timing of the "after-breakfast" dose related to the serum cortisol and sparse pharmacokinetic (PK) sampling draw.</li> <li>o To correct an error regarding Safety Analyses.</li> <li>o To clarify rescreening and informed consent form (ICF) procedures.</li> <li>o To revise Exclusion #14 to include "or allergic rhinitis"</li> <li>o To add "inhibitors" after all references to "Leukotriene"</li> <li>o To include information regarding Interim analysis data for Part 1</li> <li>o To clarify that the primary endpoint assessment will be performed at completion of Week 12 rather than Week 14.</li> <li>o To update Schedules of Events as applicable</li> <li>o To update references, correct minor inconsistencies and typographical errors</li> </ul>
--------------	---

Notes:

---

## **Interruptions (globally)**

Were there any global interruptions to the trial? No

## **Limitations and caveats**

None reported